US20170137489A1 - Process for the Synthesis of Therapeutic Peptides - Google Patents
Process for the Synthesis of Therapeutic Peptides Download PDFInfo
- Publication number
- US20170137489A1 US20170137489A1 US15/332,208 US201615332208A US2017137489A1 US 20170137489 A1 US20170137489 A1 US 20170137489A1 US 201615332208 A US201615332208 A US 201615332208A US 2017137489 A1 US2017137489 A1 US 2017137489A1
- Authority
- US
- United States
- Prior art keywords
- lys
- cys
- trp
- tyr
- thr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 157
- 238000000034 method Methods 0.000 title claims abstract description 73
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 22
- 230000015572 biosynthetic process Effects 0.000 title abstract description 45
- 238000003786 synthesis reaction Methods 0.000 title abstract description 45
- 102000004196 processed proteins & peptides Human genes 0.000 title description 32
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 273
- 229920005989 resin Polymers 0.000 claims description 152
- 239000011347 resin Substances 0.000 claims description 152
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 84
- 238000003776 cleavage reaction Methods 0.000 claims description 72
- 230000007017 scission Effects 0.000 claims description 70
- 230000008878 coupling Effects 0.000 claims description 63
- 238000010168 coupling process Methods 0.000 claims description 63
- 238000005859 coupling reaction Methods 0.000 claims description 63
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 46
- -1 hexafluorophosphate Chemical compound 0.000 claims description 44
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 43
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 38
- 125000006239 protecting group Chemical group 0.000 claims description 30
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 27
- 238000005406 washing Methods 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 23
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 claims description 23
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 22
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 22
- 239000000010 aprotic solvent Substances 0.000 claims description 18
- 239000012317 TBTU Substances 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 14
- 238000003756 stirring Methods 0.000 claims description 14
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 claims description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 12
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims description 12
- 238000001704 evaporation Methods 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 230000003213 activating effect Effects 0.000 claims description 9
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical class C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims description 9
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Substances CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 claims description 9
- ONOURAAVVKGJNM-SCZZXKLOSA-N (2s,3r)-2-azaniumyl-3-phenylmethoxybutanoate Chemical compound [O-]C(=O)[C@@H]([NH3+])[C@@H](C)OCC1=CC=CC=C1 ONOURAAVVKGJNM-SCZZXKLOSA-N 0.000 claims description 8
- JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 claims description 8
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 8
- QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 8
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 7
- 230000001376 precipitating effect Effects 0.000 claims description 7
- 230000008961 swelling Effects 0.000 claims description 7
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- ZAAVUWIYUMVQJG-UHFFFAOYSA-N 2,3,5,6-tetramethylpyridine Chemical compound CC1=CC(C)=C(C)N=C1C ZAAVUWIYUMVQJG-UHFFFAOYSA-N 0.000 claims description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 4
- QXTIBZLKQPJVII-UHFFFAOYSA-N triethylsilicon Chemical compound CC[Si](CC)CC QXTIBZLKQPJVII-UHFFFAOYSA-N 0.000 claims description 4
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 claims description 3
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 claims description 3
- WNAHIZMDSQCWRP-UHFFFAOYSA-N dodecane-1-thiol Chemical compound CCCCCCCCCCCCS WNAHIZMDSQCWRP-UHFFFAOYSA-N 0.000 claims description 3
- 229940121382 ghrelin analogues Drugs 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 claims description 3
- HCATUIMBJIDQDT-UHFFFAOYSA-N 2,4,6-trimethylpyrimidine Chemical compound CC1=CC(C)=NC(C)=N1 HCATUIMBJIDQDT-UHFFFAOYSA-N 0.000 claims description 2
- NAUGUUNRDWGECM-UHFFFAOYSA-N 2,6-ditert-butyl-n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 NAUGUUNRDWGECM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 239000007790 solid phase Substances 0.000 abstract description 8
- 101100387911 Caenorhabditis elegans dop-2 gene Proteins 0.000 description 98
- 229940024606 amino acid Drugs 0.000 description 98
- 235000001014 amino acid Nutrition 0.000 description 49
- 101100387915 Caenorhabditis elegans dop-4 gene Proteins 0.000 description 45
- 101150097115 dop-3 gene Proteins 0.000 description 41
- RDRBIXSNGAYLPT-UHFFFAOYSA-N CC1=CC=C(COC2=CC3=C(C=C2)C(NC(=O)OCC2C4=C(C=CC=C4)C4=C2C=CC=C4)C2=C(O3)C=CC=C2)C=C1 Chemical compound CC1=CC=C(COC2=CC3=C(C=C2)C(NC(=O)OCC2C4=C(C=CC=C4)C4=C2C=CC=C4)C2=C(O3)C=CC=C2)C=C1 RDRBIXSNGAYLPT-UHFFFAOYSA-N 0.000 description 39
- 150000001413 amino acids Chemical class 0.000 description 38
- 239000000243 solution Substances 0.000 description 32
- 239000002253 acid Substances 0.000 description 25
- 238000011282 treatment Methods 0.000 description 25
- 150000001408 amides Chemical class 0.000 description 24
- CDMVTQHQSAPTJJ-OCZUONHDSA-N (2r)-2-[[(2s)-2-[[(2s,3r)-2-[[(2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CS)C(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](N)CS)C1=CC=CC=C1 CDMVTQHQSAPTJJ-OCZUONHDSA-N 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 23
- 230000002045 lasting effect Effects 0.000 description 23
- 108700024539 octapeptide-Trp(8)- somatostatin Proteins 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 17
- FZTIWOBQQYPTCJ-UHFFFAOYSA-N 4-[4-(4-carboxyphenyl)phenyl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(O)=O)C=C1 FZTIWOBQQYPTCJ-UHFFFAOYSA-N 0.000 description 13
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
- 229960000553 somatostatin Drugs 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical group NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229910001873 dinitrogen Inorganic materials 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 239000002516 radical scavenger Substances 0.000 description 6
- 238000010532 solid phase synthesis reaction Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 238000010647 peptide synthesis reaction Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 150000003839 salts Chemical group 0.000 description 5
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 description 4
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 4
- 238000011097 chromatography purification Methods 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 4
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 3
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- WPSXZFTVLIAPCN-WDSKDSINSA-N Val-Cys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CS)C(O)=O WPSXZFTVLIAPCN-WDSKDSINSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000012296 anti-solvent Substances 0.000 description 3
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000004237 preparative chromatography Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- ADOHASQZJSJZBT-AREMUKBSSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-AREMUKBSSA-N 0.000 description 2
- CSMYOORPUGPKAP-IBGZPJMESA-N (2r)-3-(acetamidomethylsulfanyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSCNC(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 CSMYOORPUGPKAP-IBGZPJMESA-N 0.000 description 2
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- UXUOVYKDMGFUDU-UHFFFAOYSA-N 2,2,5,7,8-pentamethyl-3,4-dihydrochromene-6-sulfonyl chloride Chemical compound C1CC(C)(C)OC2=C1C(C)=C(S(Cl)(=O)=O)C(C)=C2C UXUOVYKDMGFUDU-UHFFFAOYSA-N 0.000 description 2
- SNDPXSYFESPGGJ-UHFFFAOYSA-N 2-aminopentanoic acid Chemical compound CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 2
- BJBUEDPLEOHJGE-UHFFFAOYSA-N 3-hydroxyproline Chemical compound OC1CCNC1C(O)=O BJBUEDPLEOHJGE-UHFFFAOYSA-N 0.000 description 2
- JDDWRLPTKIOUOF-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-[[4-[2-[bis(4-methylphenyl)methylamino]-2-oxoethoxy]phenyl]-(2,4-dimethoxyphenyl)methyl]carbamate Chemical compound COC1=CC(OC)=CC=C1C(C=1C=CC(OCC(=O)NC(C=2C=CC(C)=CC=2)C=2C=CC(C)=CC=2)=CC=1)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JDDWRLPTKIOUOF-UHFFFAOYSA-N 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- VWUIXKXOSWOJBR-UHFFFAOYSA-N CC(C)NC(CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CC=C(C2=CC=CC=C2)C=C1)C(=O)C(C)C VWUIXKXOSWOJBR-UHFFFAOYSA-N 0.000 description 2
- WXQWMDFDTJSDFQ-UHFFFAOYSA-N CC(C)NC(CC1=CC=CC=C1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CC=CC=C1)C(=O)C(C)C WXQWMDFDTJSDFQ-UHFFFAOYSA-N 0.000 description 2
- WTDRDQBEARUVNC-ZCFIWIBFSA-N D-DOPA Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-ZCFIWIBFSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- TVOOGUNBIWAURO-KATARQTJSA-N Lys-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N)O TVOOGUNBIWAURO-KATARQTJSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002952 polymeric resin Substances 0.000 description 2
- 229920005990 polystyrene resin Polymers 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 238000005086 pumping Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 239000003930 superacid Substances 0.000 description 2
- 229920003002 synthetic resin Polymers 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 2
- VQJGUUHKSTYEGE-GCYSTPHZSA-N (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1.N1[C@H](C(=O)O)C[C@@H](O)C1 VQJGUUHKSTYEGE-GCYSTPHZSA-N 0.000 description 1
- BMJRTKDVFXYEFS-MGBGTMOVSA-N (2r)-2,6-bis(9h-fluoren-9-ylmethoxycarbonylamino)hexanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@@H](C(=O)O)CCCCNC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 BMJRTKDVFXYEFS-MGBGTMOVSA-N 0.000 description 1
- FQRURPFZTFUXEZ-MRVPVSSYSA-N (2s)-2,3,3,3-tetrafluoro-2-(n-fluoroanilino)propanoic acid Chemical compound OC(=O)[C@](F)(C(F)(F)F)N(F)C1=CC=CC=C1 FQRURPFZTFUXEZ-MRVPVSSYSA-N 0.000 description 1
- YPJJGMCMOHDOFZ-ZETCQYMHSA-N (2s)-2-(1-benzothiophen-3-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CSC2=C1 YPJJGMCMOHDOFZ-ZETCQYMHSA-N 0.000 description 1
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 description 1
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 description 1
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 description 1
- XQIRYUNKLVPVRR-KRWDZBQOSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC)C(O)=O)C3=CC=CC=C3C2=C1 XQIRYUNKLVPVRR-KRWDZBQOSA-N 0.000 description 1
- YPFNACALNKVZNK-MFNIMNRCSA-N (2s)-2-[(2-aminoacetyl)amino]-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3r)-1-[[2-[[(2s)-1-[[(2s)-1-[[(2s)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-hydroxy-1- Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CN)[C@@H](C)O)C1=CC=CC=C1 YPFNACALNKVZNK-MFNIMNRCSA-N 0.000 description 1
- WBZIGVCQRXJYQD-YFKPBYRVSA-N (2s)-2-amino-3-(1,3-thiazol-4-yl)propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CSC=N1 WBZIGVCQRXJYQD-YFKPBYRVSA-N 0.000 description 1
- PDRJLZDUOULRHE-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-2-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=N1 PDRJLZDUOULRHE-ZETCQYMHSA-N 0.000 description 1
- DFZVZEMNPGABKO-ZETCQYMHSA-N (2s)-2-amino-3-pyridin-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CN=C1 DFZVZEMNPGABKO-ZETCQYMHSA-N 0.000 description 1
- VOIZSAUUYAGTMS-LURJTMIESA-N (2s)-2-amino-3-thiophen-3-ylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC=1C=CSC=1 VOIZSAUUYAGTMS-LURJTMIESA-N 0.000 description 1
- FQFVANSXYKWQOT-ZETCQYMHSA-N (2s)-2-azaniumyl-3-pyridin-4-ylpropanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=NC=C1 FQFVANSXYKWQOT-ZETCQYMHSA-N 0.000 description 1
- FMUMEWVNYMUECA-LURJTMIESA-N (2s)-2-azaniumyl-5-methylhexanoate Chemical compound CC(C)CC[C@H](N)C(O)=O FMUMEWVNYMUECA-LURJTMIESA-N 0.000 description 1
- UHPQFNXOFFPHJW-UHFFFAOYSA-N (4-methylphenyl)-phenylmethanamine Chemical compound C1=CC(C)=CC=C1C(N)C1=CC=CC=C1 UHPQFNXOFFPHJW-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- OJYOOHSQOIDDOO-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)piperidine-4-carboxylic acid Chemical compound C1CC(C(=O)O)CCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 OJYOOHSQOIDDOO-UHFFFAOYSA-N 0.000 description 1
- FVTVMQPGKVHSEY-UHFFFAOYSA-N 1-AMINOCYCLOBUTANE CARBOXYLIC ACID Chemical compound OC(=O)C1(N)CCC1 FVTVMQPGKVHSEY-UHFFFAOYSA-N 0.000 description 1
- WOXWUZCRWJWTRT-UHFFFAOYSA-N 1-amino-1-cyclohexanecarboxylic acid Chemical compound OC(=O)C1(N)CCCCC1 WOXWUZCRWJWTRT-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- PAJPWUMXBYXFCZ-UHFFFAOYSA-N 1-aminocyclopropanecarboxylic acid Chemical compound OC(=O)C1(N)CC1 PAJPWUMXBYXFCZ-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- DFPYXQYWILNVAU-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1=CC=C2N(O)N=NC2=C1 DFPYXQYWILNVAU-UHFFFAOYSA-N 0.000 description 1
- OVSKIKFHRZPJSS-UHFFFAOYSA-N 2,4-D Chemical compound OC(=O)COC1=CC=C(Cl)C=C1Cl OVSKIKFHRZPJSS-UHFFFAOYSA-N 0.000 description 1
- OMGHIGVFLOPEHJ-UHFFFAOYSA-N 2,5-dihydro-1h-pyrrol-1-ium-2-carboxylate Chemical compound OC(=O)C1NCC=C1 OMGHIGVFLOPEHJ-UHFFFAOYSA-N 0.000 description 1
- GGOMDIDNDRWXCA-UHFFFAOYSA-N 2-[2-aminoethyl-[2-[(2-oxo-1h-pyrimidin-6-yl)amino]acetyl]amino]acetic acid Chemical compound NCCN(CC(O)=O)C(=O)CNC1=CC=NC(=O)N1 GGOMDIDNDRWXCA-UHFFFAOYSA-N 0.000 description 1
- VRFJLUHAQPBTLE-UHFFFAOYSA-N 2-aminopiperidine-1-carboxylic acid Chemical compound NC1CCCCN1C(O)=O VRFJLUHAQPBTLE-UHFFFAOYSA-N 0.000 description 1
- RRRCPCOJPQLWEP-UHFFFAOYSA-N 3-hydroxytriazolo[4,5-b]pyridine Chemical compound C1=CN=C2N(O)N=NC2=C1.C1=CN=C2N(O)N=NC2=C1 RRRCPCOJPQLWEP-UHFFFAOYSA-N 0.000 description 1
- UQTZMGFTRHFAAM-ZETCQYMHSA-N 3-iodo-L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(I)=C1 UQTZMGFTRHFAAM-ZETCQYMHSA-N 0.000 description 1
- ZZOPJRZTQNZIQM-UHFFFAOYSA-N 4-(2-aminoethyl)-2-methylpiperazine-1-carboxylic acid Chemical compound CC1CN(CCN)CCN1C(O)=O ZZOPJRZTQNZIQM-UHFFFAOYSA-N 0.000 description 1
- QASBCTGZKABPKX-UHFFFAOYSA-N 4-(methylsulfanyl)phenol Chemical compound CSC1=CC=C(O)C=C1 QASBCTGZKABPKX-UHFFFAOYSA-N 0.000 description 1
- DPDPQQHHTHKSRN-UHFFFAOYSA-N 4-aminooxane-4-carboxylic acid Chemical compound OC(=O)C1(N)CCOCC1 DPDPQQHHTHKSRN-UHFFFAOYSA-N 0.000 description 1
- HFXAFXVXPMUQCQ-BYPYZUCNSA-N 4-oxo-L-proline Chemical compound OC(=O)[C@@H]1CC(=O)CN1 HFXAFXVXPMUQCQ-BYPYZUCNSA-N 0.000 description 1
- PMQQFSDIECYOQV-UHFFFAOYSA-N 5,5-dimethyl-1,3-thiazolidin-3-ium-4-carboxylate Chemical compound CC1(C)SCNC1C(O)=O PMQQFSDIECYOQV-UHFFFAOYSA-N 0.000 description 1
- 101710161788 Adropin Proteins 0.000 description 1
- 102100030805 Adropin Human genes 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010051479 Bombesin Proteins 0.000 description 1
- 102000013585 Bombesin Human genes 0.000 description 1
- YNXLOPYTAAFMTN-SBUIBGKBSA-N C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 Chemical compound C([C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)C1=CC=C(O)C=C1 YNXLOPYTAAFMTN-SBUIBGKBSA-N 0.000 description 1
- 102100024881 C3 and PZP-like alpha-2-macroglobulin domain-containing protein 8 Human genes 0.000 description 1
- ZIQFBKJAYQENDE-UHFFFAOYSA-N C=C(=C)NC1(C(=O)C(=C)=C)CCOCC1 Chemical compound C=C(=C)NC1(C(=O)C(=C)=C)CCOCC1 ZIQFBKJAYQENDE-UHFFFAOYSA-N 0.000 description 1
- UHCUYHVHZOOJPX-UHFFFAOYSA-N CC(C)C(=O)C1CCN(C(C)C)CC1 Chemical compound CC(C)C(=O)C1CCN(C(C)C)CC1 UHCUYHVHZOOJPX-UHFFFAOYSA-N 0.000 description 1
- FZSXWQPKTJMXOF-UHFFFAOYSA-N CC(C)NC(C(=O)C(C)C)C(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound CC(C)NC(C(=O)C(C)C)C(C1=CC=CC=C1)C1=CC=CC=C1 FZSXWQPKTJMXOF-UHFFFAOYSA-N 0.000 description 1
- YVMUIKHIUMZYNX-UHFFFAOYSA-N CC(C)NC(CC1=CC=C(C(=O)C2=CC=CC=C2)C=C1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CC=C(C(=O)C2=CC=CC=C2)C=C1)C(=O)C(C)C YVMUIKHIUMZYNX-UHFFFAOYSA-N 0.000 description 1
- IMXLNVKRCIIRTE-UHFFFAOYSA-N CC(C)NC(CC1=CC=CO1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CC=CO1)C(=O)C(C)C IMXLNVKRCIIRTE-UHFFFAOYSA-N 0.000 description 1
- IRAYMRQKUSONON-UHFFFAOYSA-N CC(C)NC(CC1=CC=CS1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CC=CS1)C(=O)C(C)C IRAYMRQKUSONON-UHFFFAOYSA-N 0.000 description 1
- FYLKEXQGXAIRGE-UHFFFAOYSA-N CC(C)NC(CC1=CCC=C1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CCC=C1)C(=O)C(C)C FYLKEXQGXAIRGE-UHFFFAOYSA-N 0.000 description 1
- LGVOSXODWONXCW-UHFFFAOYSA-N CC(C)NC(CC1=CCC=N1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CCC=N1)C(=O)C(C)C LGVOSXODWONXCW-UHFFFAOYSA-N 0.000 description 1
- DCGKJSODQYRNPF-UHFFFAOYSA-N CC(C)NC(CC1=CSC2=CC=CC=C12)C(=O)C(C)C Chemical compound CC(C)NC(CC1=CSC2=CC=CC=C12)C(=O)C(C)C DCGKJSODQYRNPF-UHFFFAOYSA-N 0.000 description 1
- CIXYDFRUSMWSRO-UHFFFAOYSA-N CC(C)NC(CC1=NC=CC=C1)C(=O)C(C)C Chemical compound CC(C)NC(CC1=NC=CC=C1)C(=O)C(C)C CIXYDFRUSMWSRO-UHFFFAOYSA-N 0.000 description 1
- FOTAXIVANGHTHB-UHFFFAOYSA-N CC(C)NC1(C(=O)C(C)C)CCNCC1 Chemical compound CC(C)NC1(C(=O)C(C)C)CCNCC1 FOTAXIVANGHTHB-UHFFFAOYSA-N 0.000 description 1
- MFTOFEOKDBEBDJ-UHFFFAOYSA-N CC(C)NCCN(CC(=O)C(C)C)C(=O)CN1C=CC(N)=NC1=O Chemical compound CC(C)NCCN(CC(=O)C(C)C)C(=O)CN1C=CC(N)=NC1=O MFTOFEOKDBEBDJ-UHFFFAOYSA-N 0.000 description 1
- VRKGYRHBTRMSQZ-UHFFFAOYSA-N CC(C)NCCN1CCN(CC(=O)C(C)C)CC1 Chemical compound CC(C)NCCN1CCN(CC(=O)C(C)C)CC1 VRKGYRHBTRMSQZ-UHFFFAOYSA-N 0.000 description 1
- SZTJRAITOHZIDV-UHFFFAOYSA-N CC1=C(F)C(F)=C(CC(NC(C)C)C(=O)C(C)C)C(F)=C1F Chemical compound CC1=C(F)C(F)=C(CC(NC(C)C)C(=O)C(C)C)C(F)=C1F SZTJRAITOHZIDV-UHFFFAOYSA-N 0.000 description 1
- ITOSLKBQHJBEGI-GZGNHOFSSA-N CCCN(C[C@@H](C1)C(N(CCCN(C)CC(C)=O)C(NCC)=O)=O)[C@H](C2)[C@H]1c1cccc3c1c2c[nH]3 Chemical compound CCCN(C[C@@H](C1)C(N(CCCN(C)CC(C)=O)C(NCC)=O)=O)[C@H](C2)[C@H]1c1cccc3c1c2c[nH]3 ITOSLKBQHJBEGI-GZGNHOFSSA-N 0.000 description 1
- LLMPSXJDVUDLPG-UHFFFAOYSA-N CCOC1=CC2=C(C=C1)C(N)C1=CC=CC=C1O2 Chemical compound CCOC1=CC2=C(C=C1)C(N)C1=CC=CC=C1O2 LLMPSXJDVUDLPG-UHFFFAOYSA-N 0.000 description 1
- FRMBFPLWFVNIPS-UHFFFAOYSA-N CCOC1=CC=C(C(N)C2=C(OC)C=C(C)C=C2)C=C1.COC1=C(C(N)C2=CC=C(OCC(=O)CNC(C3=CC=C(C)C=C3)C3=CC=C(C)C=C3)C=C2)C=CC(C)=C1.COC1=C(C(N)C2=CC=C(OCC(=O)CNCC3=CC=C(C)C=C3)C=C2)C=CC(C)=C1 Chemical compound CCOC1=CC=C(C(N)C2=C(OC)C=C(C)C=C2)C=C1.COC1=C(C(N)C2=CC=C(OCC(=O)CNC(C3=CC=C(C)C=C3)C3=CC=C(C)C=C3)C=C2)C=CC(C)=C1.COC1=C(C(N)C2=CC=C(OCC(=O)CNCC3=CC=C(C)C=C3)C=C2)C=CC(C)=C1 FRMBFPLWFVNIPS-UHFFFAOYSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100025892 Complement C1q tumor necrosis factor-related protein 1 Human genes 0.000 description 1
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
- 150000008574 D-amino acids Chemical class 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- 108010004460 Gastric Inhibitory Polypeptide Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 101001084254 Homo sapiens Peptidyl-tRNA hydrolase 2, mitochondrial Proteins 0.000 description 1
- 101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
- 101000598103 Homo sapiens Tuberoinfundibular peptide of 39 residues Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
- JLSKPBDKNIXMBS-VIFPVBQESA-N L-tryptophanamide Chemical compound C1=CC=C2C(C[C@H](N)C(N)=O)=CNC2=C1 JLSKPBDKNIXMBS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 108010008364 Melanocortins Proteins 0.000 description 1
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 1
- 101710151321 Melanostatin Proteins 0.000 description 1
- 101710200814 Melanotropin alpha Proteins 0.000 description 1
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 1
- 101710122877 Muellerian-inhibiting factor Proteins 0.000 description 1
- 101100297651 Mus musculus Pim2 gene Proteins 0.000 description 1
- DTERQYGMUDWYAZ-UHFFFAOYSA-N N-acetyl-N-thioacetyl-Lysine Natural products CC(=O)NCCCCC(N)C(O)=O DTERQYGMUDWYAZ-UHFFFAOYSA-N 0.000 description 1
- 102100038819 Neuromedin-B Human genes 0.000 description 1
- 101800001639 Neuromedin-B Proteins 0.000 description 1
- 102400000064 Neuropeptide Y Human genes 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 108700020797 Parathyroid Hormone-Related Proteins 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 108010088847 Peptide YY Proteins 0.000 description 1
- 102100029909 Peptide YY Human genes 0.000 description 1
- 102100030867 Peptidyl-tRNA hydrolase 2, mitochondrial Human genes 0.000 description 1
- 108010004684 Pituitary adenylate cyclase-activating polypeptide Proteins 0.000 description 1
- 102000002808 Pituitary adenylate cyclase-activating polypeptide Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102100040918 Pro-glucagon Human genes 0.000 description 1
- 102100036829 Probable peptidyl-tRNA hydrolase Human genes 0.000 description 1
- 102100024028 Progonadoliberin-1 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100022831 Somatoliberin Human genes 0.000 description 1
- 101710142969 Somatoliberin Proteins 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
- CUTPSEKWUPZFLV-WISUUJSJSA-N Thr-Cys Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CS)C(O)=O CUTPSEKWUPZFLV-WISUUJSJSA-N 0.000 description 1
- 108010018369 Urotensin II Proteins 0.000 description 1
- 102000050488 Urotensin II Human genes 0.000 description 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 description 1
- VEPFBRYUKDVICO-UHFFFAOYSA-N [CH2-][C+](=O)CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1 Chemical compound [CH2-][C+](=O)CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1 VEPFBRYUKDVICO-UHFFFAOYSA-N 0.000 description 1
- LXZYKNDUDLLEFO-UHFFFAOYSA-N [CH2-][C+](=O)CCCN1CC2=CC(Cl)=C(O)C(O)=C2CC(C2=CC=C(O)C=C2)C1 Chemical compound [CH2-][C+](=O)CCCN1CC2=CC(Cl)=C(O)C(O)=C2CC(C2=CC=C(O)C=C2)C1 LXZYKNDUDLLEFO-UHFFFAOYSA-N 0.000 description 1
- ITQAQJCZOYAOBA-UHFFFAOYSA-N [CH2-][C+](=O)CCCN1CCC2=C(CC1)SC(N)=N2 Chemical compound [CH2-][C+](=O)CCCN1CCC2=C(CC1)SC(N)=N2 ITQAQJCZOYAOBA-UHFFFAOYSA-N 0.000 description 1
- ZUVIKTNYYHMVNZ-UHFFFAOYSA-N [CH2-][C+](=O)CCCNC12CC3CC(CC(C3)C1)C2 Chemical compound [CH2-][C+](=O)CCCNC12CC3CC(CC(C3)C1)C2 ZUVIKTNYYHMVNZ-UHFFFAOYSA-N 0.000 description 1
- TZFUEUHJSRMYAX-QMMMGPOBSA-N [CH2-][C+](=O)[C@@H](N)CC1=CC(O)=C(O)C=C1 Chemical compound [CH2-][C+](=O)[C@@H](N)CC1=CC(O)=C(O)C=C1 TZFUEUHJSRMYAX-QMMMGPOBSA-N 0.000 description 1
- YUGCIVCQLDSJGX-UHFFFAOYSA-N [CH2-][C+]1=NC(C2=CC=CC=C2)=CN1 Chemical compound [CH2-][C+]1=NC(C2=CC=CC=C2)=CN1 YUGCIVCQLDSJGX-UHFFFAOYSA-N 0.000 description 1
- UGUVLMPQVMNQRZ-STQMWFEESA-N [H]N([H])[C@@H](CC1=CC=C(O)C(O)=C1)C(=O)NCCCC[C@H](N)C(C)=O Chemical compound [H]N([H])[C@@H](CC1=CC=C(O)C(O)=C1)C(=O)NCCCC[C@H](N)C(C)=O UGUVLMPQVMNQRZ-STQMWFEESA-N 0.000 description 1
- DMKOOOIPMANSAU-FHWLQOOXSA-N [H]N([H])[C@@H](CC1=CC=C(O)C(O)=C1)C(=O)NCCCC[C@H](NC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1)C(C)=O Chemical compound [H]N([H])[C@@H](CC1=CC=C(O)C(O)=C1)C(=O)NCCCC[C@H](NC(=O)[C@@H](N)CC1=CC(O)=C(O)C=C1)C(C)=O DMKOOOIPMANSAU-FHWLQOOXSA-N 0.000 description 1
- WWHDLOUNEOWPBL-SYYKKAFVSA-N [H]N1C[C@H](C(=O)N(CCCN(C)C[C+]([CH2-])=O)C(=O)NCC)C[C@]2([H])C3=C4\C(=CN\C4=C/C=C/3)C[C@@]12[H] Chemical compound [H]N1C[C@H](C(=O)N(CCCN(C)C[C+]([CH2-])=O)C(=O)NCC)C[C@]2([H])C3=C4\C(=CN\C4=C/C=C/3)C[C@@]12[H] WWHDLOUNEOWPBL-SYYKKAFVSA-N 0.000 description 1
- IEBRMBJGEKMDEB-OAHLLOKOSA-N [H][C@@]12CC3=CC=C(O)C(O)=C3C3=C1C(=CC=C3)CCN2C[C+]([CH2-])=O Chemical compound [H][C@@]12CC3=CC=C(O)C(O)=C3C3=C1C(=CC=C3)CCN2C[C+]([CH2-])=O IEBRMBJGEKMDEB-OAHLLOKOSA-N 0.000 description 1
- LEXWVCQJAUFZCV-MRXNPFEDSA-N [H][C@@]12CC3=CC=C(OC)C(O)=C3C3=C1C(=CC=C3)CCN2C[C+]([CH2-])=O Chemical compound [H][C@@]12CC3=CC=C(OC)C(O)=C3C3=C1C(=CC=C3)CCN2C[C+]([CH2-])=O LEXWVCQJAUFZCV-MRXNPFEDSA-N 0.000 description 1
- KCUXAGHLEPDWBJ-VIFPVBQESA-N [H][C@]1(NCCC[C+]([CH2-])=O)CCC2=C(C1)SC(N)=N2 Chemical compound [H][C@]1(NCCC[C+]([CH2-])=O)CCC2=C(C1)SC(N)=N2 KCUXAGHLEPDWBJ-VIFPVBQESA-N 0.000 description 1
- BWNBQXZTGXJXQL-FMRBYIFOSA-N [H][C@]12CC(CSCC(=O)O)CN(CCC)[C@]1([H])C/C1=C/NC3=C1C2=CC=C3 Chemical compound [H][C@]12CC(CSCC(=O)O)CN(CCC)[C@]1([H])C/C1=C/NC3=C1C2=CC=C3 BWNBQXZTGXJXQL-FMRBYIFOSA-N 0.000 description 1
- MUGBVVZVYSYUCS-GZGNHOFSSA-N [H][C@]12C[C@@H](C(=O)N(CCCN(C)C[C+]([CH2-])=O)C(=O)NCC)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 Chemical compound [H][C@]12C[C@@H](C(=O)N(CCCN(C)C[C+]([CH2-])=O)C(=O)NCC)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 MUGBVVZVYSYUCS-GZGNHOFSSA-N 0.000 description 1
- QOWCFRAJLUQDFY-ZCHNWHJFSA-N [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@@H](CC(=O)CSC[C@H]3CN(CCC)[C@]4([H])C/C5=C/NC6=CC=CC(=C65)[C@@]4([H])C3)C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)CC(=O)[C@H](CC)NC(=O)[C@H](CCCC[Na])CC(=O)[C@@H](C/C4=C/NC5=C4C=CC=C5)NC(=O)[C@H](CC4=CC=C(O)C=C4)CC3=O)CN(CCC)[C@]1([H])CC1=CNC3=CC=CC2=C13 Chemical compound [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@@H](CC(=O)CSC[C@H]3CN(CCC)[C@]4([H])C/C5=C/NC6=CC=CC(=C65)[C@@]4([H])C3)C(=O)N[C@H]3CSSC[C@@H](C(=O)N[C@H](C(N)=O)[C@@H](C)O)CC(=O)[C@H](CC)NC(=O)[C@H](CCCC[Na])CC(=O)[C@@H](C/C4=C/NC5=C4C=CC=C5)NC(=O)[C@H](CC4=CC=C(O)C=C4)CC3=O)CN(CCC)[C@]1([H])CC1=CNC3=CC=CC2=C13 QOWCFRAJLUQDFY-ZCHNWHJFSA-N 0.000 description 1
- RDUISYHARQPPSD-KDAIGSHJSA-N [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@H](NC(=O)CSC[C@H]3CN(CCC)[C@]4([H])CC5=CN/C6=C/C=C\C(=C56)[C@@]4([H])C3)C(=O)C(C)C)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C\C2=C13 Chemical compound [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@H](NC(=O)CSC[C@H]3CN(CCC)[C@]4([H])CC5=CN/C6=C/C=C\C(=C56)[C@@]4([H])C3)C(=O)C(C)C)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C\C2=C13 RDUISYHARQPPSD-KDAIGSHJSA-N 0.000 description 1
- UUXLLUXKCWOVNN-SXASJSGMSA-N [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@H](NC(C)C)C(=O)C(C)C)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C\C2=C13 Chemical compound [H][C@]12C[C@@H](CSCC(=O)NCCCC[C@H](NC(C)C)C(=O)C(C)C)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C\C2=C13 UUXLLUXKCWOVNN-SXASJSGMSA-N 0.000 description 1
- NXANLYVDPRMUKL-MZMPZRCHSA-N [H][C@]12C[C@@H](CSC[C+]([CH2-])=O)CN(C)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 Chemical compound [H][C@]12C[C@@H](CSC[C+]([CH2-])=O)CN(C)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 NXANLYVDPRMUKL-MZMPZRCHSA-N 0.000 description 1
- DRGHWZZEEAMHLT-XFQXTVEOSA-N [H][C@]12C[C@@H](CSC[C+]([CH2-])=O)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 Chemical compound [H][C@]12C[C@@H](CSC[C+]([CH2-])=O)CN(CCC)[C@]1([H])CC1=CN/C3=C/C=C/C2=C\13 DRGHWZZEEAMHLT-XFQXTVEOSA-N 0.000 description 1
- OEOVVXLPOIXNDY-IAGOWNOFSA-N [H][C@]12OCCN(CCC[C+]([CH2-])=O)[C@]1([H])CCC1=CC=C(O)C=C12 Chemical compound [H][C@]12OCCN(CCC[C+]([CH2-])=O)[C@]1([H])CCC1=CC=C(O)C=C12 OEOVVXLPOIXNDY-IAGOWNOFSA-N 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- HOPRXXXSABQWAV-UHFFFAOYSA-N anhydrous collidine Natural products CC1=CC=NC(C)=C1C HOPRXXXSABQWAV-UHFFFAOYSA-N 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- WTOFYLAWDLQMBZ-LURJTMIESA-N beta(2-thienyl)alanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CS1 WTOFYLAWDLQMBZ-LURJTMIESA-N 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 125000003636 chemical group Chemical group 0.000 description 1
- UTBIMNXEDGNJFE-UHFFFAOYSA-N collidine Natural products CC1=CC=C(C)C(C)=N1 UTBIMNXEDGNJFE-UHFFFAOYSA-N 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- RBNPZEHAODHBPZ-UHFFFAOYSA-M dihydroxyaluminium Chemical compound O.O.NCC(=O)O[Al] RBNPZEHAODHBPZ-UHFFFAOYSA-M 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- QNRXNRGSOJZINA-UHFFFAOYSA-N indoline-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)CC2=C1 QNRXNRGSOJZINA-UHFFFAOYSA-N 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-RXMQYKEDSA-N l-pipecolic acid Natural products OC(=O)[C@H]1CCCCN1 HXEACLLIILLPRG-RXMQYKEDSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002865 melanocortin Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- OFYAYGJCPXRNBL-LBPRGKRZSA-N naphthalen-2-yl-3-alanine Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-LBPRGKRZSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 description 1
- CQYBNXGHMBNGCG-RNJXMRFFSA-N octahydroindole-2-carboxylic acid Chemical compound C1CCC[C@H]2N[C@H](C(=O)O)C[C@@H]21 CQYBNXGHMBNGCG-RNJXMRFFSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- TVIDEEHSOPHZBR-AWEZNQCLSA-N para-(benzoyl)-phenylalanine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1C(=O)C1=CC=CC=C1 TVIDEEHSOPHZBR-AWEZNQCLSA-N 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 1
- NPDBDJFLKKQMCM-UHFFFAOYSA-N tert-butylglycine Chemical compound CC(C)(C)C(N)C(O)=O NPDBDJFLKKQMCM-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- DZLNHFMRPBPULJ-UHFFFAOYSA-N thioproline Chemical compound OC(=O)C1CSCN1 DZLNHFMRPBPULJ-UHFFFAOYSA-N 0.000 description 1
- BJBUEDPLEOHJGE-IMJSIDKUSA-N trans-3-hydroxy-L-proline Chemical compound O[C@H]1CC[NH2+][C@@H]1C([O-])=O BJBUEDPLEOHJGE-IMJSIDKUSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- HFNHAPQMXICKCF-USJMABIRSA-N urotensin-ii Chemical compound N([C@@H](CC(O)=O)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@@H](C(C)C)C(O)=O)C(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@@H](N)CCC(O)=O)[C@@H](C)O HFNHAPQMXICKCF-USJMABIRSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 1
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
- ORQXBVXKBGUSBA-QMMMGPOBSA-N β-cyclohexyl-alanine Chemical compound OC(=O)[C@@H](N)CC1CCCCC1 ORQXBVXKBGUSBA-QMMMGPOBSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
- C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
- C07K1/063—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups for alpha-amino functions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel process for the large-scale synthesis of therapeutic peptides containing unnatural or man-made amino acids.
- the method is scalable to large volumes and allows for the cost effective manufacturing of highly-pure peptides.
- Solid-phase peptide synthesis is a highly successful method introduced first by Merrifield in 1963 (Merrifield, R. B., J. Amer. Chem. Soc., 1963, 85:2149-54). Numerous peptides have been synthesized with this technique since then. Methods used in the prior art to chemically synthesize peptides and proteins are reviewed in Kent, S. B. H., Ann. Rev. Biochem., 1988, 57:957-89. Solid-phase synthesis allows for the synthesis of natural peptides which are difficult to express in bacteria, the incorporation of unnatural or synthetic amino acids, peptide backbone modification and the synthesis of D-proteins containing D-amino acids.
- stepwise solid-phase synthesis Two strategies for the assembly of peptide chains by solid-phase synthesis have been used: 1). stepwise solid-phase synthesis and 2). solid-phase fragment condensation.
- stepwise SPPS the C-terminal amino acid in the form of an N- ⁇ -protected, and if necessary, side-chain-protected reactive derivative, is covalently coupled either directly or by means of a suitable linker to a “solid”-support, e.g., a polymeric resin, typically swollen in an organic solvent.
- the N- ⁇ -protective group is removed, and the subsequent protected amino acids are added in a stepwise fashion.
- the side chain protective groups are removed and the peptide is cleaved from the resin. The cleaving/de-protecting process may be done in separate steps or at the same time.
- solid-phase fragment condensation the target sequence is assembled by consecutive condensation of fragments on a solid support using protected fragments prepared by stepwise SPPS.
- Fmoc fluorenylmethyloxycarbonyl
- Cleavage of the peptide from the resin with removal of side chain protecting groups is achievable by acidolysis using an acidic solution, such as trifluoroacetic acid (TFA).
- TIPS Triisopropylsilane
- TES Triethylsilane
- EDT 1,2-ethanedithiol
- DTT dithiothreitol
- Amino acids have reactive moieties at the N- and C-termini which facilitate amino acid coupling during synthesis.
- the reactive side chain functional groups found on most amino acids can interact with free termini or other side chain groups during synthesis and peptide elongation and negatively influence yield and purity.
- chemical groups referred to as “protecting groups” are used to bind to the specific amino acid functional groups to “block” or “protect” the functional group from nonspecific reactions.
- Side chain protecting groups are known as permanent or semi-permanent protecting groups because they can withstand the multiple cycles of chemical treatment during synthesis and are only removed generally during treatment with strong acids after peptide synthesis is completed.
- Such impurities may include dehydrated or oxidized species or impurities related to the attachment of all or part of the resin-linker to the peptide—these impurities may be subsequently difficult to remove. As such, there is a need for developing an efficient large-scale method for producing therapeutic peptides.
- Resins may be made from polystyrene or other polymeric materials, such as polymers of ethylene oxide, e.g. PEG based resins or a mixture of both, e.g. “hybrid” or PEG-polystyrene resins.
- Commonly used resins for manufacturing of peptide amides by the Fmoc SPPS route include polystyrene-based resins combined with a linker suitable for releasing a fully de-protected peptide amide upon treatment with high concentrations of acid.
- Rink Amide resins include the Rink Amide resins, for example, Rink Amide resin, Rink Amide MBHA resin, and Rink Amide AM resin.
- Rink Amide resins release a fully de-protected peptide amide from the resin when treated with a high percentage v/v of acid in the cleavage cocktail—for example, 80-95% v/v trifluoroacetic acid (TFA) is typically used.
- TFA trifluoroacetic acid
- the paper describes the synthesis of two peptides on this resin—the first with no side chain protecting groups (Z-Val-Gly-Ala-Pro-NH2) where cleavage from the resin on 0.5 g scale is effected by pumping an acidic cleavage mixture (TFA:1,2-dichloroethane 2:98 v/v) through the resin in a glass column; the second peptide ( ⁇ -MSH), a 13 amino acid peptide that contains side chain-protected groups (tert-Butyl, Trt, Mtr, and Boc), was cleaved from the resin by pumping an acidic cleavage mixture (TFA/1,2-dichloroethane-/1,2-ethanedithiol 2:98:0.1) through a column with the resin. Two further steps with high concentrations of acid and heating (TFA/water 9:1 at 30° C., followed by 95% TFA with scavengers at 50° C.) were required to remove all the side chain
- Sieber Amide resin While not stated implicitly in the article above, the main usefulness of Sieber Amide resin (as the xanthenyl resin became known) was to produce fully side chain protected peptides for use in subsequent fragment condensation reactions. This is achievable through the use of low percentages v/v of acid in the cleavage cocktail—typically 1-5% v/v. According to a commercial supplier (Novabiochem®, Merck KGaA), Sieber resin is “[a] hyper acid-labile linker (resin) for the FMOC SPPS of protected peptide amides via mild 1% TFA cleavage.”
- the present invention provides a novel process for the large-scale synthesis of therapeutic peptides which comprises stepwise solid-phase Fmoc-chemistry.
- the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
- a dipolar aprotic solvent is used.
- dipolar aprotic solvent may be selected from dimethylformamide (DMF), dimethylacetamide (DMA) or N-methylpyrrolidone (NMP), or combinations thereof.
- DMF dimethylformamide
- DMA dimethylacetamide
- NMP N-methylpyrrolidone
- DMF is used as the dipolar aprotic solvent.
- the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
- a base is used.
- Said base may be a tertiary amine base or a mixture thereof, and selected from N,N-diisopropylethylamine (DIEA), triethylamine (TEA), N-methylmorpholine (NMM), 2,4,6-trimethylpyrimidine (TMP, also known as collidine), 2,3,5,6-tetramethylpyridine (TEMP), 2,6-di-tert-butyl-4-dimethylaminopyridine (DBDMAP), or 4-dimethylaminopyridine (DMAP).
- DIEA N,N-diisopropylethylamine
- TEA triethylamine
- NMM N-methylmorpholine
- TMP 2,4,6-trimethylpyrimidine
- EMP 2,3,5,6-tetramethylpyridine
- DBDMAP 2,6-di-tert-butyl-4-dimethylaminopyridine
- DMAP 4-dimethylamino
- a preferred embodiment of the immediately foregoing aspect of the present invention is characterized in that the base used in step (d) is a tertiary amine, and that in a more preferred embodiment, said base is N,N-diisopropylethylamine (DIEA).
- DIEA N,N-diisopropylethylamine
- the present invention provides a process for the synthesis of therapeutic peptides comprising the steps of:
- the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
- cleavage cocktail used in step (i) of the process as defined above is comprised of TFA, one or more scavenger and DCM wherein said scavenger is selected from the group consisting of Triisopropylsilane (TIPS), Triethylsilane (TES), phenol, anisole, thioanisole, water, 1,2-ethanedithiol (EDT), 1-dodecanethiol, dithiothreitol (DTT) and indole, provided that the percentage of TFA in said cleavage cocktail does not exceed 25%.
- TIPS Triisopropylsilane
- TES Triethylsilane
- EDT 1,2-ethanedithiol
- DTT dithiothreitol
- a preferred embodiment of the immediately foregoing aspect of the present invention is characterized in that said scavenger is selected from the group consisting of TIPS, TES, anisole and water.
- cleavage cocktail used in step (i) as defined above is comprised of TFA, one or more scavenger and DCM wherein said scavenger may be selected from the group consisting of TIPS, TES, anisole and water provided that the percentage of TFA in said cleavage cocktail does not exceed 25%.
- cleavage cocktail consists of 15 to 25% v/v TFA with 2.5 to 12% v/v TIPS and 62.5 to 82.5% v/v DCM; and even more preferred to that said cleavage cocktail consists of 20% v/v TFA with 10% v/v TIPS and 70% v/v DCM.
- a further preferred embodiment of the process of present invention as defined above with steps (a) to (k) is that the resulting peptide is cleaved from the Sieber Amide resin concurrently with the de-protection of the side chain protecting groups.
- Another preferred embodiment of the present invention is characterized in that the Fmoc group is initially removed from the resin using piperidine in DMF.
- the Fmoc group is initially removed from the resin using piperidine in DMF wherein the concentration of said piperidine in DMF is less than 20% (v/v) and more preferably about 15% (v/v).
- step (f) of the process of the present invention the coupling of the activated Fmoc-amino acids is carried out using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with a base such as N,N-diisopropylethylamine (DIEA) in a dipolar aprotic solvent such as DMF, alone or in combination.
- HCTU (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate)
- TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3
- the amino acid residues are coupled using a “coupling reagent combination” selected from the group consisting of TBTU/HOBt/DIEA, HBTU/HOBt/DIEA, HATU/DIEA, HCTU/DIEA, DIC/HOBt, DIC/HOAt, HATU/HOBt/DIEA and HCTU/HOBt/DIEA, more preferably selected from the group consisting of HCTU/DIEA and TBTU/HOBt/DIEA.
- a “coupling reagent combination” selected from the group consisting of TBTU/HOBt/DIEA, HBTU/HOBt/DIEA, HATU/DIEA, HCTU/DIEA, DIC/HOBt, DIC/HOAt, HATU/HOBt/DIEA and HCTU/HOBt/DIEA, more preferably selected from the group consisting of HCTU/DIEA and TBTU/HOB
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (a) (the Fmoc-Sieber-Amide resin is initially swelled using 1 to 3 treatments of 7 to 12 vols of DMF for up to 1 hour, even more preferred, 3 treatments of 10 vols of DMF lasting 10 to 30 minutes per treatment.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (b), the Fmoc group on the Sieber resin is de-protected using 1 to 2 treatments with a solution of piperidine in DMF (10-20% v/v) lasting 5 to 20 minutes, even more preferred 2 treatments of 15% v/v piperidine in DMF lasting 10 minutes.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (c), the de-protected resin is washed 3 to 5 times with 7 to 12 vols of DMF each wash lasting up to 5 minutes, even more preferred, 3 washes with 10 vols DMF each wash lasting up to 5 minutes.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (d), 1.2-2.0 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid is activated for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for up to 5 minutes; and more preferably 1.5 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid is activated for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for 1 to 2 minutes.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (f), 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) is used with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 4 to 10 vols DMF for 30 to 120 minutes at ambient temperature; and more preferably, 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) is used with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 5 to 7 vols of DMF for 60 minutes at 15 to 30° C.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (g), the resin is washed after each coupling, 2 to 4 times with 7 to 12 vols of DMF for up to 5 minutes; and in a more preferred embodiment, the resin after each coupling is washed 2 times with 10 vols DMF for up to 5 minutes.
- a preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (k), after combining the filtrates and evaporating the combination:
- Another preferred embodiment of the process of the present invention is characterized in that it comprises the following successive steps (a) to (j):
- steps (a) to (j) are further defined as follows:
- side chain protecting groups contemplated include but are not limited to, methoxytrimethylbenzene-sulfonyl (Mtr), 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride (Pmc), 4,4-dimethyloxybenhydryl (Mbh) and 2,4,6-trimethoxybenzyl (Tmob).
- Mtr methoxytrimethylbenzene-sulfonyl
- Pmc 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride
- Mbh 4,4-dimethyloxybenhydryl
- Tmob 2,4,6-trimethoxybenzyl
- the present invention also provides for those situations when it is desirable to retain certain side chain protecting groups during and after cleavage. For instance, it is important to retain the acetamidomethyl (Acm) side chain protecting group on Cys so that the completed peptide can be purified in its linear form and thereafter cyclized when the protecting groups are removed and a disulfide bridge is formed between two Cys residues.
- Acm acetamidomethyl
- FIG. 1 graph depicting the head to head comparison of peptides synthesized using a Rink Amide resin to those synthesized using a Sieber Amide resin under similar synthetic procedures. Peptides of varying lengths from 5 amino acids to 30 amino acids were made, according to the procedures described herein, and the synthetic yield was measured. For each peptide length (reported down the y-axis of the graph), the percent yield (as indicated by the x-axis) using Rink Amide resin is represented by the top bar and the percent yield using Sieber Amide resin is represented by the bottom bar. For each peptide synthesized, i.e. a 5 amino acid sequence, two 8 amino acid sequences, an 8 amino acid sequence modified with one or more dopamine moieties and a 30 amino acid sequence, use of Sieber Amide resin resulted in higher % yields.
- FIG. 2 graph depicting the synthesis yield reproducibility on a 2 g to 2200 g scale when using Sieber Amide resin for the synthesis of a 5 amino acid peptide. As reported, a synthesis yield of about 80% was consistently achieved for every scale.
- FIG. 3 graph depicting the relative cost based on material employed for the synthesis of an 8 amino acid peptide and a 30 amino acid peptide using a Rink Amide resin versus Sieber Amide resin.
- the relative cost based on materials used for those peptides synthesized using a Rink Amide resin for a 8 amino acid peptide and 30 amino acid peptide are represented by the top bars whereas the relative cost for the same peptide using a Sieber Amide resin are represented by the bottom bars for each peptide.
- the relative cost of using a Sieber Amide resin is less than that of a Rink Amide resin.
- Rink amide resins are used in solid phase peptide synthesis to prepare peptide amides utilizing Fmoc-protected amino acids. Coupling of the first amino acid can be achieved using typical methods of amide bond formation.
- the peptide sequence is assembled under basic or neutral conditions on Rink amide resin then the completed peptide is cleaved from the resin under acid conditions.
- the peptide is cleaved from Rink Amide resin using greater than 80% TFA v/v. (Stathopoulos, P.; Papas, S.; and Tsikaris, V., J. Pept.
- Rink Amide resin is traditionally low. Examples of Rink resins are:
- Sieber Amide resin an example of the “super acid-sensitive” resins (Sieber, P., Tetrahedron Lett., 1987, 28(19):2107-10), is primarily used for the synthesis of peptide amides retaining side chain protecting groups including, but not limited to, tert-butyloxycarbonyl (Boc) and tert-butyl ether (tBu) when used with low concentrations of trifluoroacetic acid (TFA) (1-5% v/v) in the cleavage cocktail.
- Boc tert-butyloxycarbonyl
- tBu tert-butyl ether
- the Inventors attempted the synthesis of an acid sensitive 8-residue peptide amide using Sieber Amide resin. They found that linear SPPS could be done using Sieber Amide resin together with Fmoc chemistry. The Inventors discovered that by adjusting the conditions, a high concentration of acid, i.e. TFA, is not required for cleavage of the final product from the Sieber resin. In addition, it was discovered that side chain protecting groups could be removed concurrently with a cleavage of the resulting peptide from the Sieber Amide resin when a “medium” strength TFA/TIPS/DCM cleavage cocktail is used.
- the Inventors also attempted to use Sieber Amide resin to synthesize other peptides from 5 to 30 amino acids in length and peptides containing unnatural amino acids as well troublesome naturally-occurring amino acids such as tryptophan, cysteine and arginine.
- the Inventors discovered that peptides containing unnatural or problematic amino acids could be synthesized using Sieber Amide resin with medium TFA concentration during cleavage. It was also discovered that peptides containing arginine could be synthesized using Sieber Amide resin although higher TFA concentration was necessary during cleavage particularly if sulfonyl side chain protecting groups are present
- Sieber Amide resin when used in a manner contrary to that disclosed in the literature, resulted in higher yields of purer crude product.
- the Inventors discovered that the synthesis yield increased from 18-30% when Rink Amide resin was used, to 78-83% when Sieber Amide resin was used for the preparation of the ghrelin analogue H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 , as reported in WO 2004/014415.
- the Greek letter psi “ ⁇ ” is used herein to indicate that a peptide bond has been replaced by a pseudopeptide bond.
- the format of the ⁇ term is A 1 - ⁇ -(X-X′)A 2 wherein A 1 is the amino acyl radical whose carbonyl group has been modified to X and A 2 is the amino acyl radical whose ⁇ -amino group has been modified to X′.
- X and X′ are shown as strings of element symbols separated by a bond, e.g., Tyr- ⁇ -(CH 2 —NH)Gly.
- cleavage cocktail refers to a mixture of reagents used to remove, or cleave, the assembled peptide from a resin.
- a cleavage cocktail also serves to remove all side chain protecting groups and the N-terminal protecting groups.
- resin refers to either Fmoc-Sieber Amide resin or Sieber Amide resin to which one or more amino acids have been attached.
- room temperature (or ambient temperature) means a temperature range of from 15-30° C.
- the Invention describes a novel method of synthesizing a peptide comprising step-wise solid-phase chemistry.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of somatostatin, bombesin, VIP, PACAP, GHRH, glucagon, calcitonin, peptide YY, neuromedin B, PTH, PTHrP, PTH2, GLP-1, Urotensin-II, ghrelin, melanocortin, MIS, LHRH, adropin, GIP, neuropeptide Y, IGF-1, dopamine-somatostatin chimeras, and ACTH.
- somatostatin an analogue of somatostatin, bombesin, VIP, PACAP, GHRH, glucagon, calcitonin, peptide YY, neuromedin B, PTH, PTHrP, PTH2, GLP-1, Urotensin-II, ghrelin, melanocortin, MIS, LHRH
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin or dopamine-somatostatin chimeras.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin of the formula (I)
- a 1 is Aib, Apc or Inp
- a 2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- a 3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- a 4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl);
- a 5 is Apc, Dab, Dap, Lys, Orn, or deleted;
- R 1 is hydrogen
- R 2 is OH or NH
- a 1 is Aib, Ape or lnp
- a 2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- a 3 is D-Bal, D-Bpa, D-Dip, D-1 Nal, D-2Nal, or D-Trp;
- a 4 is Orn, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl);
- a 5 is Apc, Lys, or deleted.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of ghrelin of formula (I) as defined above wherein
- a 1 is Apc or lnp
- a 2 is D-Bal, D-Bip, D-1 Nal, or D-2Nal;
- a 3 is D-Bal, D-1 Nal, D-2Nal, or D-Trp;
- a 4 is 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl);
- a 5 is Ape or Lys.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of ghrelin selected from H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 , H-Inp-D-2B al-D-Trp-Phe-Apc-NH 2 , H-Inp-D-Bal-D-Trp-2Thi-Apc-NH 2 , and H-Inp-D-Bal-D-Trp-Taz-Apc-NH 2 , and more particularly H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 .
- ghrelin selected from H-Inp-D-Bal-D-Trp-Phe-Apc-NH 2 , H-Inp-D-2B al-D-Trp-Phe-Apc-NH 2 , H-Inp-D-Bal-D-
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras, i.e. a chimeric molecule comprising somatostatin or an analogue thereof and at least one dopamine moiety.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras including the structure of Dop A or DopA-Lys(DopA), wherein Lys is L-Lysine, unless expressly designated as D-Lys, A is 1-13, for example Dop1, Dop2, Dop3, Dop4, Dop5, Dop6, Dop7, Dop8, Dop9, Dop10, Dop11, Dop12, Dop13.
- the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras including the structure of DopA-Lys(DopA), and the compound Dop2-D-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH 2 .
- Fmoc-Sieber Amide resin (Merck Chemicals, Darmstadt, Germany) is initially swelled using 1 to 3 treatments of 7 to 12 vols, 10 vols preferred, of DMF (Samsung, Korea), in addition, for up to 1 hour, although 3 treatments lasting about 10-30 minutes each are preferred.
- Fmoc de-protection of the Sieber Amide resin is accomplished using 1 to 2 treatments of a solution of piperidine in DMF (about 10-20% v/v, 15% v/v preferred) lasting 5 to 20 minutes, although 2 treatments lasting 10 minutes each are preferred.
- the de-protected resin is washed 3 to 5 times with 7 to 12 vols of DMF lasting for up to 5 minutes, although 3 washes of 10 vols of DMF lasting up to 5 minutes for each wash is preferred.
- the Fmoc-amino acids are activated for coupling to the resin by dissolving the Fmoc-amino acid together with the coupling reagent(s) in DMF, adding a base such as DIEA (SAFC, Gillingham, United Kingdom), stirring for up to 5 minutes (1-2 minutes preferred), and charging to the resin in the reactor.
- a base such as DIEA (SAFC, Gillingham, United Kingdom)
- DIEA SAFC, Gillingham, United Kingdom
- Fmoc-amino acid coupling are carried out using about 1.2 to 2.0 mol equivs (1.5 mol equivs preferred) of Fmoc-amino acid relative to the resin using HCTU (Merck Chemicals) or TBTU/HOBt (0.5 to 2.0 mol equivs relative to the Fmoc amino acid) (both TBTU and HOBt obtained from SAFC) with a base, preferably DIEA (about 1.5 to 3.5 mol equivs relative to the Fmoc-amino acid, although specific equivs are preferred for particular amino acids), in DMF (4 to 10 vols, 5 to 7 vols preferred) lasting 30 to 120 minutes (although duration varies depending on the amino acid being coupled, however, 60 minutes is preferred for most amino acids) at an ambient temperature (preferably 15 to 30° C.).
- the resin is washed 2 to 4 times with 7 to 12 vols of DMF (2 washed of 10 vols of DMF is preferred) each washing lasting up to 5 minutes.
- the desired peptide is cleaved from the resin and any side chain protecting groups are “de-protected” using a cleavage cocktail consisting of about 15 to 25% v/v TFA (Rhodia, Lyon, France) (although preferably 15 to 20% v/v, and approximately 20% v/v is more preferred) with about 2.5 to 12% v/v TIPS (SAFC, Gillingham, United Kingdom) (although preferably 5-10% v/v, and about 10% v/v is more preferred) used as a scavenger with the remainder of the cleavage cocktail comprising 62.5 to 82.5% v/v DCM (INEOS Chlor, Runcorn, UK) (depending on the percentage of TFA and TIPS used).
- the resin is immersed in and agitated with the cleavage cocktail for 2 to 3 hours (2.5 hours preferred) at about ambient temperature (about 15 to 30° C.). Intermittent sparging with nitrogen gas or blanketing the cleavage reaction mixture with nitrogen gas is introduced.
- the cleavage mixture containing the desired peptide and the “spent” resin is filtered.
- the “spent” resin is washed with a small volume of either fresh cleavage cocktail or a TFA/DCM (15-20:80-85 v/v) mixture (1 to 2 times using 1 to 2 vol over resin weight).
- An optional wash of a small volume of MeOH (1 to 2 times using about 1 to 2 vol over resin weight) (Univar, Dublin, Ireland) may follow.
- the peptide-rich filtrates are combined and evaporated to ⁇ 20% of the original filtrate weight ( ⁇ 15% preferred).
- the crude peptide is precipitated from the concentrated solution by an organic anti-solvent such as MtBE (Univar, Dublin, Ireland) (about 5 to 15 vols, preferably 6.5 to 10 vols), filtered, and washed with small volumes of the same organic anti-solvent (up to 3 times with about 1 to 2 vols).
- the precipitated peptide may be dried.
- Dissolution of the dry or semi-wet peptide precipitate for subsequent purification is carried out using a dilute acid such as acetic acid together with an organic solvent such as ACN (INEOS Nitriles, Rolle, Switzerland) (about % v/v depending on the solubility of the peptide and the % at which it elutes during chromatographic purification).
- a dilute acid such as acetic acid
- an organic solvent such as ACN (INEOS Nitriles, Rolle, Switzerland) (about % v/v depending on the solubility of the peptide and the % at which it elutes during chromatographic purification).
- step (i) In the synthesis of chimeric compounds such as dopamine-somatostatin chimeras, the process includes additional steps. The general procedure of these additional steps may be illustrated as follows: before step (i),
- TFA Trigger-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propanethyl-N-N-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Propane-Pro
- the titled peptide was synthesized in a 50-liter filter reactor (Buchi, Flawil, Switzerland.
- Fmoc-Sieber Amide resin was swelled with DMF (3 times 10 vol).
- the Fmoc group was de-protected by two treatments of a 15% v/v solution of piperidine (BASF, Schwarheide, Germany) in DMF (2 ⁇ 10 vols, 10 minutes each). The resin was then washed with DMF (3 ⁇ 10 vols).
- Fmoc amino acids employed (Apc, D-Trp) required Boc-protected side chains, the others (Phe, D-Bal, Inp) did not require side chain protection.
- the peptide was cleaved from the resin and its side chain-protecting groups removed using 10 vol. of a cleavage cocktail comprised of TFA/TIPS/DCM (20/10/70% v/v) for 2.5 hours.
- the peptide-containing filtrate was evaporated under reduced pressure, precipitated and washed with MtBE before being dissolved in dilute acetic acid and acetonitrile for subsequent purification.
- the synthesis yield was 80.8%, purity by HPLC 90.0%.
- the peptide was purified using a reverse-phase preparative HPLC column (Novasep, Pompey, France) packed with C 18 stationary phase (EKA Chemicals AB, Bohus, Sweden). Purification and salt exchange was performed under gradient elution using ammonium acetate and acetic acid buffers with acetonitrile as organic modifier.
- the titled peptide was synthesized in a 50-liter filter.
- the synthesis was carried out on a 0.72 mole scale (1.2 kg input resin).
- the protected amino acids employed herein can be obtained from Synthetech, Inc., Albany, Oreg., USA or Senn Chemicals, Dielsdorf, Switzerland
- the first amino acid to be coupled to the resin Fmoc-Thr(tBu)—OH (2.0 equivs.), TBTU (1.96 equivs), HOBt (1.96 equivs), and DIEA (3.0 equivs in DMF (5.5 vol)) were stirred with the resin for 60 minutes.
- the resin was drained and Fmoc-Thr(tBu)—OH was re-coupled using Fmoc-Thr(tBu)—OH (1.0 equivs), TBTU (0.98 equivs), HOBt (0.98 equivs) and DIEA (1.5 equivs) in DMF (2.8 vol) for 60 minutes.
- the Fmoc group was de-protected as outlined above and the second aminoacid, Fmoc-Cys(Acm)-OH, was coupled using the same conditions as outlined for Fmoc-Thr(tBu)—OH.
- the cycle of Fmoc de-protection, washing, Fmoc-amino acid coupling and washing was repeated for Fmoc-Abu-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Tyr(tBu)—OH, Fmoc-Cys(Acm)-OH and Fmoc-D-Lys(Fmoc)-OH in that order.
- the Fmoc-amino acid coupling steps were performed using TBTU (1.96 equivs), HOBt (1.96 equivs) and DIEA (3.0 equivs) in DMF (5.8-7 vol) for 60 minutes.
- the dopamine portion of the titled molecule i.e.
- the crude peptide was precipitated from the concentrated solution by addition to stirred MtBE (6.5 vols over residual weight post evaporation, 40 L), filtered, and washed with MtBE (1 vol over residual weight post evaporation, 6.2 L, once). Dissolution of the semi-dry peptide precipitate for subsequent cyclisation was carried out using 38 vol (45 L) over resin weight of 0.1% v/v TFA/water, with ACN (30% v/v).
- therapeutic peptides which can be synthesized using the novel process described herein, include, but are not limited to, the following:
- Dopamine-somatostatin chimeras that may be synthesized using the claimed method, include but are not limited to, those molecules as described in WO 02/100888 and WO 04/091490, as follows:
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A process for the large-scale synthesis of a therapeutic peptide using solid-phase Fmoc-chemistry.
Description
- The present invention relates to a novel process for the large-scale synthesis of therapeutic peptides containing unnatural or man-made amino acids. The method is scalable to large volumes and allows for the cost effective manufacturing of highly-pure peptides.
- Solid-phase peptide synthesis (SPPS) is a highly successful method introduced first by Merrifield in 1963 (Merrifield, R. B., J. Amer. Chem. Soc., 1963, 85:2149-54). Numerous peptides have been synthesized with this technique since then. Methods used in the prior art to chemically synthesize peptides and proteins are reviewed in Kent, S. B. H., Ann. Rev. Biochem., 1988, 57:957-89. Solid-phase synthesis allows for the synthesis of natural peptides which are difficult to express in bacteria, the incorporation of unnatural or synthetic amino acids, peptide backbone modification and the synthesis of D-proteins containing D-amino acids.
- Two strategies for the assembly of peptide chains by solid-phase synthesis have been used: 1). stepwise solid-phase synthesis and 2). solid-phase fragment condensation. In stepwise SPPS, the C-terminal amino acid in the form of an N-α-protected, and if necessary, side-chain-protected reactive derivative, is covalently coupled either directly or by means of a suitable linker to a “solid”-support, e.g., a polymeric resin, typically swollen in an organic solvent. The N-α-protective group is removed, and the subsequent protected amino acids are added in a stepwise fashion. When the desired peptide chain length has been obtained, the side chain protective groups are removed and the peptide is cleaved from the resin. The cleaving/de-protecting process may be done in separate steps or at the same time. In solid-phase fragment condensation, the target sequence is assembled by consecutive condensation of fragments on a solid support using protected fragments prepared by stepwise SPPS.
- One form of SPPS relies on fluorenylmethyloxycarbonyl (or “Fmoc”) to temporarily protect the α-amino group. With this method, the Fmoc group is covalently bound to the amino group to suppress its nucleophilicity. The C-terminal amino acid is covalently linked to the resin though a linker. Next, the Fmoc group is removed with base, such as piperidine. This liberates the amino group which is then available for reaction with an activated amino acid. Reactions are driven to completion by the use of excess (typically two- to four-fold) activated amino acid. After each de-protection and coupling step, one or more washes are performed to remove excess reagents. Cleavage of the peptide from the resin with removal of side chain protecting groups is achievable by acidolysis using an acidic solution, such as trifluoroacetic acid (TFA). It is common practice to add additional chemicals labeled as “scavengers” such as Triisopropylsilane (TIPS), Triethylsilane (TES), phenol, anisole, thioanisole, water, 1,2-ethanedithiol (EDT), 1-dodecanethiol, dithiothreitol (DTT) and indole, with the acid in the cleavage mixture to react with the liberated side chain protecting groups, thereby preventing those liberated groups from re-attaching to the cleaved peptide.
- Amino acids have reactive moieties at the N- and C-termini which facilitate amino acid coupling during synthesis. In addition, the reactive side chain functional groups found on most amino acids can interact with free termini or other side chain groups during synthesis and peptide elongation and negatively influence yield and purity. To facilitate proper amino acid synthesis with minimal side chain reactivity, chemical groups, referred to as “protecting groups” are used to bind to the specific amino acid functional groups to “block” or “protect” the functional group from nonspecific reactions. Side chain protecting groups are known as permanent or semi-permanent protecting groups because they can withstand the multiple cycles of chemical treatment during synthesis and are only removed generally during treatment with strong acids after peptide synthesis is completed.
- The current aforementioned strategies are not desirable for commercial scale production of the therapeutic peptides because the resins used therein require the peptide be removed using high concentrations of acid for cleavage of the peptide from the polymeric resin. Outside of the safety concerns of using large quantities of extremely corrosive material at large scale, special equipment may be required to permit its use. In addition, use of highly concentrated strong acids to cleave and de-protect peptides can result in serious degradation of the desired peptide resulting in low yield and/or the creation of new impurities as a result of the exposure of the peptide to strong acid for the period of time required to perform a cleavage and work-up on scale. Such impurities may include dehydrated or oxidized species or impurities related to the attachment of all or part of the resin-linker to the peptide—these impurities may be subsequently difficult to remove. As such, there is a need for developing an efficient large-scale method for producing therapeutic peptides.
- As mentioned previously, solid-phase peptide synthesis is initiated on a “solid” support or anchor. These “supports” are referred to in the industry as “resins”. Resins may be made from polystyrene or other polymeric materials, such as polymers of ethylene oxide, e.g. PEG based resins or a mixture of both, e.g. “hybrid” or PEG-polystyrene resins. Commonly used resins for manufacturing of peptide amides by the Fmoc SPPS route include polystyrene-based resins combined with a linker suitable for releasing a fully de-protected peptide amide upon treatment with high concentrations of acid. Commonly used resins include the Rink Amide resins, for example, Rink Amide resin, Rink Amide MBHA resin, and Rink Amide AM resin. Rink Amide resins release a fully de-protected peptide amide from the resin when treated with a high percentage v/v of acid in the cleavage cocktail—for example, 80-95% v/v trifluoroacetic acid (TFA) is typically used.
- In 1987, a new acid-labile resin for the solid-phase synthesis of C-terminal amides was discovered by Sieber (Tetrahedon Lett., 1987, 28(19):2107-10). This resin utilizes 9-xanthenyl group with a —OCH2— group introduced between said xanthenyl group and the polystyrene to increase acid lability. Cleavage of peptide amides from this resin is performed by very mild acidolysis. The paper describes the synthesis of two peptides on this resin—the first with no side chain protecting groups (Z-Val-Gly-Ala-Pro-NH2) where cleavage from the resin on 0.5 g scale is effected by pumping an acidic cleavage mixture (TFA:1,2-dichloroethane 2:98 v/v) through the resin in a glass column; the second peptide (α-MSH), a 13 amino acid peptide that contains side chain-protected groups (tert-Butyl, Trt, Mtr, and Boc), was cleaved from the resin by pumping an acidic cleavage mixture (TFA/1,2-dichloroethane-/1,2-ethanedithiol 2:98:0.1) through a column with the resin. Two further steps with high concentrations of acid and heating (TFA/water 9:1 at 30° C., followed by 95% TFA with scavengers at 50° C.) were required to remove all the side chain protecting groups.
- While not stated implicitly in the article above, the main usefulness of Sieber Amide resin (as the xanthenyl resin became known) was to produce fully side chain protected peptides for use in subsequent fragment condensation reactions. This is achievable through the use of low percentages v/v of acid in the cleavage cocktail—typically 1-5% v/v. According to a commercial supplier (Novabiochem®, Merck KGaA), Sieber resin is “[a] hyper acid-labile linker (resin) for the FMOC SPPS of protected peptide amides via mild 1% TFA cleavage.”
- It has been discovered that using Sieber Amide resin combined with Fmoc chemistry and a cleavage solution using certain concentrations of trifluoroacetic acid (TFA) (for example, above 10% v/v) can be used to synthesize fully de-protected peptide amides practically and on large scale (kg scale). This is a superior method for manufacturing fully de-protected peptide amides when compared to using Rink Amide resins, because:
-
- (i) it is possible to achieve greater manufacturing yields using this method
- (ii) it is possible to achieve greater purities of peptide using this method which allows for a more facile downstream purification
- (iii) it facilitates the reduced consumption of raw materials and solvents, and therefore is a more cost-effective method of manufacture
- (iv) it is a robust and reproducible method from small to large scale, therefore allowing for a facile scaling of the process.
- The present invention provides a novel process for the large-scale synthesis of therapeutic peptides which comprises stepwise solid-phase Fmoc-chemistry.
- In one aspect, the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
-
- (a) swelling Fmoc-Sieber resin (also referred to as Sieber Amide resin or Fmoc Sieber Amide resin) in a dipolar aprotic solvent;
- (b) de-protecting the Fmoc group using a solution of piperidine in a dipolar aprotic solvent;
- (c) washing the resin after Fmoc de-protection with a dipolar aprotic solvent;
- (d) activating the Fmoc-amino acids for coupling to the de-protected resin by dissolving the Fmoc-amino acid and coupling reagent(s) in a dipolar aprotic solvent then adding a base and stirring;
- (e) charging the activated Fmoc-amino acid solution to the resin in the reactor;
- (f) coupling the activated Fmoc-amino acid using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with a base in a dipolar aprotic solvent as a coupling reagent;
- (g) washing the resin after each Fmoc-amino acid coupling;
- (h) repeating steps (b)-(g) until a peptide is formed;
- (i) cleaving the desired peptide from the resin while simultaneously de-protecting the amino acid side chains using a cleavage cocktail;
- (j) filtering the cleavage mixture from the resin; and
- (k) evaporating the filtrates and precipitating and partially purifying the crude product from the concentrated solution with an organic solvent to yield a partially purified peptide.
- According to steps (a), (b), (c) and (f) of the process as defined above, a dipolar aprotic solvent is used. Such dipolar aprotic solvent may be selected from dimethylformamide (DMF), dimethylacetamide (DMA) or N-methylpyrrolidone (NMP), or combinations thereof. In a preferred embodiment DMF is used as the dipolar aprotic solvent.
- In another aspect, the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
-
- (a) swelling Fmoc-Sieber resin (also referred to as Sieber Amide resin or Fmoc Sieber Amide resin) in dimethylformamide (DMF);
- (b) de-protecting the Fmoc group using a solution of piperidine in DMF;
- (c) washing the resin after Fmoc de-protection with DMF;
- (d) activating the Fmoc-amino acids for coupling to the de-protected resin by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF then adding a base and stirring;
- (e) charging the activated Fmoc-amino acid solution to the resin in the reactor;
- (f) coupling the activated Fmoc-amino acids using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with a base in DMF as a coupling reagent;
- (g) washing the resin after each Fmoc-amino acid coupling;
- (h) repeating steps (b)-(g) until a peptide is formed;
- (i) cleaving the desired peptide from the resin while simultaneously de-protecting the amino acid side chains using a cleavage cocktail;
- (j) filtering the cleavage mixture from the resin; and
- (k) evaporating the filtrates and precipitating and partially purifying the crude product from the concentrated solution with an organic solvent to yield a partially purified peptide.
- According to step (d) of the process of the present invention as defined above, a base is used. Said base may be a tertiary amine base or a mixture thereof, and selected from N,N-diisopropylethylamine (DIEA), triethylamine (TEA), N-methylmorpholine (NMM), 2,4,6-trimethylpyrimidine (TMP, also known as collidine), 2,3,5,6-tetramethylpyridine (TEMP), 2,6-di-tert-butyl-4-dimethylaminopyridine (DBDMAP), or 4-dimethylaminopyridine (DMAP). A preferred embodiment of the immediately foregoing aspect of the present invention is characterized in that the base used in step (d) is a tertiary amine, and that in a more preferred embodiment, said base is N,N-diisopropylethylamine (DIEA).
- In another aspect, the present invention provides a process for the synthesis of therapeutic peptides comprising the steps of:
-
- (a) swelling Fmoc-Sieber resin (also referred to as Sieber Amide resin or Fmoc Sieber Amide resin) in dimethylformamide (DMF);
- (b) de-protecting the Fmoc group using a solution of piperidine in DMF;
- (c) washing the resin after Fmoc de-protection with DMF;
- (d) activating the Fmoc-amino acids for coupling to the de-protected resin by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF then adding a base and stirring;
- (e) charging the activated Fmoc-amino acid solution to the resin in the reactor;
- (f) coupling the activated Fmoc-amino acids using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with N,N-diisopropylethylamine (DIEA) in DMF as a coupling reagent;
- (g) washing the resin after each Fmoc-amino acid coupling;
- (h) repeating steps (b)-(g) until a peptide is formed;
- (i) cleaving the desired peptide from the resin while simultaneously de-protecting the amino acid side chains using a cleavage cocktail;
- (j) filtering the cleavage mixture from the resin; and
- (k) evaporating the filtrates and precipitating and partially purifying the crude product from the concentrated solution with an organic anti-solvent to yield a partially purified peptide.
- In another aspect, the present invention provides a process for the synthesis of therapeutic peptides comprising the successive steps of:
-
- (a) swelling Fmoc-Sieber resin (also referred to as Sieber Amide resin or Fmoc Sieber Amide resin) in dimethylformamide (DMF);
- (b) de-protecting the Fmoc group using a solution of piperidine in DMF;
- (c) washing the resin after Fmoc de-protection with DMF;
- (d) activating the Fmoc-amino acids for coupling to the de-protected resin by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF then adding N,N-diisopropylethylamine (DIEA) and stirring;
- (e) charging the activated Fmoc-amino acid solution to the resin in the reactor;
- (f) coupling the activated Fmoc-amino acids using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with N,N-diisopropylethylamine (DIEA) in DMF as a coupling reagent;
- (g) washing the resin after each Fmoc-amino acid coupling;
- (h) repeating steps (b)-(g) until a peptide is formed;
- (i) cleaving the desired peptide from the resin while simultaneously de-protecting the amino acid side chains using a cleavage cocktail;
- (j) filtering the cleavage mixture from the resin; and
- (k) evaporating the filtrates and precipitating and partially purifying the crude product from the concentrated solution with an organic solvent to yield a partially purified peptide.
- Another preferred embodiment of the present invention is characterized in that said cleavage cocktail used in step (i) of the process as defined above, is comprised of TFA, one or more scavenger and DCM wherein said scavenger is selected from the group consisting of Triisopropylsilane (TIPS), Triethylsilane (TES), phenol, anisole, thioanisole, water, 1,2-ethanedithiol (EDT), 1-dodecanethiol, dithiothreitol (DTT) and indole, provided that the percentage of TFA in said cleavage cocktail does not exceed 25%.
- A preferred embodiment of the immediately foregoing aspect of the present invention is characterized in that said scavenger is selected from the group consisting of TIPS, TES, anisole and water.
- Another preferred embodiment of the present invention is characterized in that said cleavage cocktail used in step (i) as defined above is comprised of TFA, one or more scavenger and DCM wherein said scavenger may be selected from the group consisting of TIPS, TES, anisole and water provided that the percentage of TFA in said cleavage cocktail does not exceed 25%.
- For peptides wherein only Boc and tBu side chain protecting groups are required to be removed, a preferred embodiment of the present invention is characterized in that said cleavage cocktail consists of 15 to 25% v/v TFA with 2.5 to 12% v/v TIPS and 62.5 to 82.5% v/v DCM; and even more preferred to that said cleavage cocktail consists of 20% v/v TFA with 10% v/v TIPS and 70% v/v DCM.
- For peptides wherein only Boc and tBu side chain protecting groups are required to be removed, a preferred embodiment of the process of the present invention as defined above is characterized in that:
-
- said cleavage cocktail used in step (i) as defined above consists of 15 to 25% v/v TFA with 2.5 to 12% v/v TIPS and the remainder of the cleavage cocktail made up to 100% with DCM; and even more preferred to that
- said cleavage cocktail used in step (i) as defined above consists of approximately 20% v/v TFA with approximately 10% v/v TIPS and 70% v/v DCM.
- A further preferred embodiment of the process of present invention as defined above with steps (a) to (k) is that the resulting peptide is cleaved from the Sieber Amide resin concurrently with the de-protection of the side chain protecting groups.
- Another preferred embodiment of the present invention is characterized in that the Fmoc group is initially removed from the resin using piperidine in DMF. In a more preferred embodiment, the Fmoc group is initially removed from the resin using piperidine in DMF wherein the concentration of said piperidine in DMF is less than 20% (v/v) and more preferably about 15% (v/v).
- According to step (f) of the process of the present invention as defined above, the coupling of the activated Fmoc-amino acids is carried out using (2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluorocorate (TBTU)/1-hydroxybenzotriazole (HOBt) with a base such as N,N-diisopropylethylamine (DIEA) in a dipolar aprotic solvent such as DMF, alone or in combination. In a preferred embodiment of any one of the foregoing aspects of the present invention, the amino acid residues are coupled using a “coupling reagent combination” selected from the group consisting of TBTU/HOBt/DIEA, HBTU/HOBt/DIEA, HATU/DIEA, HCTU/DIEA, DIC/HOBt, DIC/HOAt, HATU/HOBt/DIEA and HCTU/HOBt/DIEA, more preferably selected from the group consisting of HCTU/DIEA and TBTU/HOBt/DIEA.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (a) (the Fmoc-Sieber-Amide resin is initially swelled using 1 to 3 treatments of 7 to 12 vols of DMF for up to 1 hour, even more preferred, 3 treatments of 10 vols of DMF lasting 10 to 30 minutes per treatment.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (b), the Fmoc group on the Sieber resin is de-protected using 1 to 2 treatments with a solution of piperidine in DMF (10-20% v/v) lasting 5 to 20 minutes, even more preferred 2 treatments of 15% v/v piperidine in DMF lasting 10 minutes.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (c), the de-protected resin is washed 3 to 5 times with 7 to 12 vols of DMF each wash lasting up to 5 minutes, even more preferred, 3 washes with 10 vols DMF each wash lasting up to 5 minutes.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (d), 1.2-2.0 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid is activated for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for up to 5 minutes; and more preferably 1.5 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid is activated for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for 1 to 2 minutes.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (f), 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) is used with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 4 to 10 vols DMF for 30 to 120 minutes at ambient temperature; and more preferably, 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) is used with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 5 to 7 vols of DMF for 60 minutes at 15 to 30° C.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (g), the resin is washed after each coupling, 2 to 4 times with 7 to 12 vols of DMF for up to 5 minutes; and in a more preferred embodiment, the resin after each coupling is washed 2 times with 10 vols DMF for up to 5 minutes.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (i):
-
- the resin is immersed in the cleavage cocktail and agitated for 2 to 3 hours at an ambient temperature, and more preferably the resin is immersed and agitated for 2.5 hours, and
- the resin/cleavage cocktail solution are intermittently sparged with nitrogen gas.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above is characterized in that, in step (j):
-
- the spent resin is washed with a small volume of either fresh cleavage cocktail or TFA/DCM (20:80 v/v) 1 to 2 times;
- the spent resin is optionally washed with a small volume of MeOH.
- A preferred embodiment of the process of the present invention with the successive steps (a) to (j) as defined above, is characterized in that, in step (k), after combining the filtrates and evaporating the combination:
-
- the crude peptide is precipitated out using 5 to 15 vols MtBE;
- the precipitated peptide is dryed to the required level of dryness;
- the precipitated peptide is dissolved with dilute acid, or dilute acid with the organic modifier to be used in downstream chromatographic purification
- the peptide is purified and a salt exchange step using reverse-phase preparative chromatography is performed.
- Another preferred embodiment of the process of the present invention is characterized in that it comprises the following successive steps (a) to (j):
-
- (a) swelling the Fmoc-Sieber-Amide resin using 1 to 3 treatments of 7 to 12 vols of DMF for up to 1 hour, even more preferred, 3 treatments of 10 vols of DMF lasting 10 to 30 minutes per treatment;
- (b) de-protecting the Fmoc group on the Sieber resin using 1 to 2 treatments with a solution of piperidine in DMF (10-20% v/v) lasting 5 to 20 minutes, even more preferrably 2 treatments of 15% v/v piperidine in DMF lasting 10 minutes;
- (c) washing the de-protected resin is 3 to 5 times with 7 to 12 vols of DMF each wash lasting up to 5 minutes, even more preferably, 3 washes with 10 vols DMF each wash lasting up to 5 minutes.
- (d) activating 1.2-2.0 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid for coupling to the de-protected resin by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for 1 to 2 minutes; and more preferably activating 1.5 mol equivs (relative to the resin-batch scale) of the Fmoc-amino acid for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DIEA, stirring for 1 to 2 minutes.
- (e) charging the activated Fmoc-amino acid solution to the resin in the reactor;
- (f) coupling the Fmoc-amino acid to the deprotected resin by immersing and agitating the deprotected resin with the activated Fmoc-amino acid solution for 30-120 min at ambient temperature; said activated Fmoc-amino acid solution comprised of Fmoc-amino acid as described in (d) above along with 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 4 to 10 vols DMF at ambient temperature; and more preferably, 0.5 to 1.5 mol equivs (relative to Fmoc amino acid) of coupling reagent(s) with 1.5 to 2.5 mol equivs (relative to Fmoc amino acid) of DIEA in 5 to 7 vols of DMF for 60 minutes at 15 to 30° C.
- (g) washing the resin after each coupling, 2 to 4 times with 7 to 12 vols of DMF for up to 5 minutes; and more preferably 2 times with 10 vols DMF for up to 5 minutes;
- (h) repeating steps (b)-(g) until a peptide is formed;
- (i) cleaving the desired peptide from the resin while simultaneously de-protecting the amino acid side chains using a cleavage cocktail, by:
- immersing the resin in cleavage cocktail and agitating for 2 to 3 hours at an ambient temperature, and more preferably by immersing and agitating for 2.5 hours, and
- sparging the resin/cleavage cocktail mixture intermittently with nitrogen gas.
- (j) filtering the cleavage mixture from the resin, then
- washing the spent resin with a small volume of either fresh cleavage cocktail or TFA/DCM (20:80 v/v) 1 to 2 times; and
- optionally washing the spent resin with a small volume of MeOH.
- (k) combining the filtrate and washes and evaporating the combination, then
- precipitating the crude peptide from the combined evaporated filtrate and washes using 5 to 15 vols MtBE;
- drying the precipitated peptide to the required level of dryness;
- dissolving the precipitated peptide with dilute acid, or dilute acid with the organic modifier to be used in downstream chromatographic purification;
- purifying the peptides and performing a salt exchange step using reverse-phase preparative chromatography.
- A preferred embodiment of any one of the immediately foregoing aspects of the present invention is characterized in that steps (a) to (j) (new substeps are indicated by -#) are further defined as follows:
-
- (a) swelling the Fmoc-Sieber-Amide resin initially using 1 to 3 treatments of 7 to 12 vols of DMF for up to 1 hour, even more preferred, 3 treatments of 10 vols of DMF lasting 10 to 30 minutes per treatment;
- (b) de-protecting the Fmoc group on the Sieber resin using 1 to 2 treatments with a solution of piperidine in DMF (10-20% v/v) lasting 5 to 20 minutes, even more preferred 2 treatments of 15% v/v piperidine in DMF lasting 10 minutes;
- (c) washing the de-protected resin 3 to 5 times with 7 to 12 vols of DMF each wash lasting up to 5 minutes, even more preferred, 3 washes with 10 vols DMF each wash lasting up to 5 minutes;
- (d) activating the Fmoc-amino acids (1.2-2.0 mol equivs, or more preferred, 1.5 mol equivs relative to the resin-batch scale) for coupling by dissolving the Fmoc-amino acid and coupling reagent(s) in DMF, adding DMA, stirring for up to 5 minutes, even more preferred, stirring for 1 to 2 minutes;
- (e) charging the coupling solution to the resin in the reactor;
- (f) using 0.5 to 1.5 mol equivs of coupling reagent(s) relative to Fmoc amino acid with 1.5 to 2.5 mol equivs of DIEA relative to the Fmoc-amino acids in 4 to 10 vols DMF for 30 to 120 minutes at ambient temperature, even more preferred, using 5 to 7 vols of DMF for 60 minutes at 15 to 30° C.;
- (g). washing the resin, after each coupling, 2 to 4 times with 7 to 12 vols of DMF for up to 5 minutes, even more preferred, 2 washes with 10 vols DMF for up to 5 minutes;
- (h). repeating steps (b)-(g) until a peptide is formed;
- (i). immersing the resin in the cleavage cocktail and agitating for 2 to 3 hours at an ambient temperature, more preferred immersing and agitating the resin for 2.5 hours;
- (i-1). sparging the resin/cleavage cocktail solution with nitrogen gas intermittently;
- (j). filtering the cleavage mixture from the resin;
- (j-1). washing the spent resin with a small volume of either fresh cleavage cocktail or TFA/DCM (20:80 v/v) 1 to 2 times;
- (j-2). washing the spent resin with a small volume of MeOH;
- (k). combining the filtrates and evaporating the combination
- (k-1) precipitating a crude peptide out using 5 to 15 vols MtBE;
- (k-2). drying the precipitated peptide to the required level of dryness
- (k-3) dissolving the precipitated peptide with dilute acid, or dilute acid with the organic modifier to be used in downstream chromatographic purification
- (k-4). purifying the peptide and performing a salt exchange step using reverse-phase preparative chromatography.
- It is acknowledged that some protecting groups (e.g. 2,2,4,6,7-pentamethyl-dihydrobenzofuran-5-sulfonyl (Pbf) side chain protection of Arg) will require a higher percentage of acid, typically 50-80%, for removal of the side chain protecting group within a practical timeframe, however, all other aspects of the present invention remain the same. Other side chain protecting groups contemplated, include but are not limited to, methoxytrimethylbenzene-sulfonyl (Mtr), 2,2,5,7,8-pentamethyl-chroman-6-sulfonyl chloride (Pmc), 4,4-dimethyloxybenhydryl (Mbh) and 2,4,6-trimethoxybenzyl (Tmob).
- The present invention also provides for those situations when it is desirable to retain certain side chain protecting groups during and after cleavage. For instance, it is important to retain the acetamidomethyl (Acm) side chain protecting group on Cys so that the completed peptide can be purified in its linear form and thereafter cyclized when the protecting groups are removed and a disulfide bridge is formed between two Cys residues.
-
FIG. 1 .: graph depicting the head to head comparison of peptides synthesized using a Rink Amide resin to those synthesized using a Sieber Amide resin under similar synthetic procedures. Peptides of varying lengths from 5 amino acids to 30 amino acids were made, according to the procedures described herein, and the synthetic yield was measured. For each peptide length (reported down the y-axis of the graph), the percent yield (as indicated by the x-axis) using Rink Amide resin is represented by the top bar and the percent yield using Sieber Amide resin is represented by the bottom bar. For each peptide synthesized, i.e. a 5 amino acid sequence, two 8 amino acid sequences, an 8 amino acid sequence modified with one or more dopamine moieties and a 30 amino acid sequence, use of Sieber Amide resin resulted in higher % yields. -
FIG. 2 : graph depicting the synthesis yield reproducibility on a 2 g to 2200 g scale when using Sieber Amide resin for the synthesis of a 5 amino acid peptide. As reported, a synthesis yield of about 80% was consistently achieved for every scale. -
FIG. 3 : graph depicting the relative cost based on material employed for the synthesis of an 8 amino acid peptide and a 30 amino acid peptide using a Rink Amide resin versus Sieber Amide resin. The relative cost based on materials used for those peptides synthesized using a Rink Amide resin for a 8 amino acid peptide and 30 amino acid peptide are represented by the top bars whereas the relative cost for the same peptide using a Sieber Amide resin are represented by the bottom bars for each peptide. As reported, the relative cost of using a Sieber Amide resin is less than that of a Rink Amide resin. - Most stepwise solid-phase synthesis requires use of a polystyrene resin for synthesis of peptide amides. Rink amide resins are used in solid phase peptide synthesis to prepare peptide amides utilizing Fmoc-protected amino acids. Coupling of the first amino acid can be achieved using typical methods of amide bond formation. The peptide sequence is assembled under basic or neutral conditions on Rink amide resin then the completed peptide is cleaved from the resin under acid conditions. Typically the peptide is cleaved from Rink Amide resin using greater than 80% TFA v/v. (Stathopoulos, P.; Papas, S.; and Tsikaris, V., J. Pept. Sci., 2006, 12:227-37). Stronger acids or higher concentrations of TFA sometimes cleaves some of the Rink linker from the polystyrene support and introduces colored impurities into the cleaved product. As such for some peptides, the synthesis yield using Rink Amide resin is traditionally low. Examples of Rink resins are:
- The lability of the linker of “super acid-sensitive” or “hyper acid-sensitive” resin to low concentrations of acid allows for fully-protected peptides to be released from the resin. Typically, 1-5% v/v TFA is required for peptide cleavage. With the exception of the decreased potency of the acid required for cleavage, these resins are similar to the Rink Amide resins, namely they are a polystyrene matrix of similar bead size with similar loading capacity. As such, these resins are useful for convergent synthesis employing the same Fmoc chemistry with respect to loading of the first and coupling of subsequent residues.
- Sieber Amide resin, an example of the “super acid-sensitive” resins (Sieber, P., Tetrahedron Lett., 1987, 28(19):2107-10), is primarily used for the synthesis of peptide amides retaining side chain protecting groups including, but not limited to, tert-butyloxycarbonyl (Boc) and tert-butyl ether (tBu) when used with low concentrations of trifluoroacetic acid (TFA) (1-5% v/v) in the cleavage cocktail.
- Since Sieber Amide resin is traditionally used for Fmoc solid-phase synthesis, it is necessary that the amino acids be Fmoc-protected. Accordingly, the protecting groups that remain after completion of the peptide synthesis need to be cleaved. The cleavage of the remaining protecting groups requires high acidolytic conditions, such as up to 95% TFA containing up to 5% ethanediol and up to 5% 4-(methylmercapto)phenol (Sieber, P., Tetrahedron Lett., 1987, 28(19):2107-10).
- The Inventors attempted the synthesis of an acid sensitive 8-residue peptide amide using Sieber Amide resin. They found that linear SPPS could be done using Sieber Amide resin together with Fmoc chemistry. The Inventors discovered that by adjusting the conditions, a high concentration of acid, i.e. TFA, is not required for cleavage of the final product from the Sieber resin. In addition, it was discovered that side chain protecting groups could be removed concurrently with a cleavage of the resulting peptide from the Sieber Amide resin when a “medium” strength TFA/TIPS/DCM cleavage cocktail is used. With some optimization, the Inventors discovered that it was possible to synthesize full-length peptides with protected amino acids, particularly those with Boc, tBu and/or Trt protecting groups, and then release a fully de-protected peptide amide from the resin while minimizing peptide degradation.
- The Inventors also attempted to use Sieber Amide resin to synthesize other peptides from 5 to 30 amino acids in length and peptides containing unnatural amino acids as well troublesome naturally-occurring amino acids such as tryptophan, cysteine and arginine. The Inventors discovered that peptides containing unnatural or problematic amino acids could be synthesized using Sieber Amide resin with medium TFA concentration during cleavage. It was also discovered that peptides containing arginine could be synthesized using Sieber Amide resin although higher TFA concentration was necessary during cleavage particularly if sulfonyl side chain protecting groups are present
- Surprisingly, Sieber Amide resin, when used in a manner contrary to that disclosed in the literature, resulted in higher yields of purer crude product. For example, the Inventors discovered that the synthesis yield increased from 18-30% when Rink Amide resin was used, to 78-83% when Sieber Amide resin was used for the preparation of the ghrelin analogue H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, as reported in WO 2004/014415. For other peptides, such as dopamine-somatostatin chimeras, the Inventors reported that synthesis yield using the Sieber Amide resin was 72.6 to 80.8% compared to commonly used resins such as the Rink Amide family of resins (e.g. Rink Amide MBHA resin, Rink Amide AM resin, Rink Amide resin) yielding 13 to 71% under identical conditions. The inventors discovered that by using Sieber Amide resin increased yield on average by up to 50% compared to using Rink Amide resin. Further, yield was reproducible between batches and on scale-up from 2 g up to 2.2 kg. The comparative yields using Rink Amide versus using Sieber Amide resin under identical conditions to synthesize peptides of varying lengths, i.e. 5 amino acids in length to 30 amino acids in length, are reported in
FIG. 1 . In each comparison, use of Sieber Amide resin resulted in higher synthesis yields, 70% versus 10%. As a result, relative cost percentage, based on peptide length, was less when Sieber Amide resin is use in place of the traditional Rink Amide resinFIG. 3 . The Inventors also demonstrate the reproducibility of synthesis yield using Sieber Amide resin inFIG. 2 . - Further, commonly-used Rink Amide resins require high concentrations of TFA, usually 80-95% v/v, for cleavage of the final peptide from the resin. The Inventors discovered that by using Sieber Amide resin, only 10-25% TFA was required. As stated previously, higher concentrations of TFA can result in serious degradation of the peptide over time, as well as the presence of impurities such as those derived from the attachment of all or part of the resin linker to the peptide which subsequently may be difficult to remove. Moreover, work-up after cleavage is faster using the claimed process since less acid is needed during final cleavage
- In addition, it was found that it was possible to reduce quantities of Fmoc-amino acids, coupling reagents, and solvents using Sieber Amide resin, without affecting yield or purity of the peptide produced
- Certain amino acids present in compounds of the invention are represented herein as follows:
-
- A3c 1-amino-1-cyclopropanecarboxylic acid
- A4c 1-amino-1-cyclobutanecarboxylic acid
- A5c 1-amino-1-cyclopentanecarboxylic acid
- A6c 1-amino-1-cyclohexanecarboxylic acid
- Abu α-aminobutyric acid
- Acc 1-amino-1-cyclo(C3-C9)alkyl carboxylic acid
- Act 4-amino-4-carboxytetrahydropyran, i.e.:
-
- Aepa 4-(2-aminoethyl)-1-carboxy methyl-piperazine, represented by the structure:
-
- Aib α-aminoisobutyric acid
- Ala or A alanine
- β-Ala beta-alanine
- Apc amino piperidinylcarboxylic acid, i.e.:
-
- Arg or R arginine
- hArg homoarginine
- Asn or N asparagine
- Asp or D aspartic acid
- Bal 3-benzothienylalanine, i.e.:
-
- Bip 4,4′-biphenylalanine, i.e.:
-
- Bpa 4-benzoylphenylalanine, i.e.:
-
- Caeg N-(2-aminoethyl)-N-(2-cytosinyl-1-oxo-ethyl)-glycine, represented by the structure:
-
- Cha β-cyclohexylalanine;
- Cys or C cysteine;
- Dab 2,4-diaminobutyric acid, (α,γ-diaminobutyric acid);
- Dap 2,3-diaminopropionic acid, (α,β-diaminopropionic acid);
- Dip β,β-diphenylalanine, i.e.:
-
- Dhp 3,4-dehydroproline
-
Dmt 5,5-dimethylthiazolidine-4-carboxylic acid - 2-Fua 13-(2-furyl)-alanine, i.e.:
-
- Gln or Q glutamine
- Glu or E glutamic acid
- Gly or G glycine
- His or H histidine
- 3-Hyp trans-3-hydroxy-L-proline, i.e., (2S,3S)-3-hydroxypyrrolidine-2-carboxylic acid;
- 4-Hyp 4-hydroxyproline, i.e., (2S,4R)-4-hydroxypyrrolidine-2-carboxylic acid;
- Ile or I isoleucine
- Inc indoline-2-carboxylic acid
- Inp isonipecotic acid, i.e.:
-
- Ktp 4-ketoproline
- Leu or L leucine
- hLeu homoleucine
- Lys or K lysine
- Lys(Ac) lysine(acetyl)
- Met or M methionine
- 1-Nal β-(1-naphthyl)alanine:
- 2-Nal β-(2-naphthyl)alanine;
- Nle norleucine
- Nva norvaline
- Oic octahydroindole-2-carboxylic acid
- Orn ornithine
- 2-Pal β-(2-pyridyl)-alanine, i.e.,
-
- 3-Pal β-(3-pyridyl)-alanine, i.e.:
-
- 4-Pal β-(4-pyridyl)-alanine, i.e.:
-
- Pff pentafluorophenylalanine, i.e.
-
- Phe or F phenylalanine
- hPhe homophenylalanine
- Pim 2′-(4-phenyl)imidazolyl, i.e.:
-
- Pip pipecolic acid
- Pro or P proline
- Ser or S serine
- Ser(Bzl) serine(O-benzyl)
- Taz β-(4-thiazolyl)alanine, i.e.,
-
- 2-Thi β-(2-thienyl)alanine, i.e.:
-
- 3-Thi β-(3-thienyl)alanine, i.e.:
-
- Thr or T threonine
- Thr(Bzl) threonine(O-benzyl)
- Thz thiazolidine-4-carboxylic acid
-
Tic 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid - Tle tert-leucine
- Trp or W tryptophan
- (N-Me)D-Trp Na-methyl-D-tryptophan
- Tyr or Y tyrosine
- 3-I-Tyr 3-iodo-tyrosine
- Val or V valine
- Dop1″ is meant a compound having the structure of:
-
- “Dop2” is meant a compound having the structure of:
-
- “Dop3” is meant a compound having the structure of:
-
- “Dop4” is meant a compound having the structure of:
-
- “Dop5” is meant a compound having the structure of:
-
- “Dop6” is meant a compound having the structure of:
-
- “Dop7” is meant a compound having the structure of:
-
- “Dop8” is meant a compound having the structure of:
-
- “Dop9” is meant a compound having the structure of:
-
- “Dop10” is meant a compound having the structure of:
-
- “Dop11” is meant a compound having the structure of:
-
- “Dop12” is meant a compound having the structure of:
-
- “Dop13” is meant a compound having the structure of:
-
- Lys(Dop2) has the structure of:
-
- Dop2-Lys(Dop2) has the structure of:
-
- Lys(Dop5) has the structure of:
-
- Dop5-Lys(Dop5) has the structure of:
- The Greek letter psi “Ψ” is used herein to indicate that a peptide bond has been replaced by a pseudopeptide bond. In an amino acid sequence name, the format of the Ψ term is A1-Ψ-(X-X′)A2 wherein A1 is the amino acyl radical whose carbonyl group has been modified to X and A2 is the amino acyl radical whose α-amino group has been modified to X′. X and X′ are shown as strings of element symbols separated by a bond, e.g., Tyr-Ψ-(CH2—NH)Gly.
- The application employs the following abbreviations:
-
- Ac acetyl
- ACN acetonitrile
- Acm acetamidomethyl
- AM aminomethyl
- Boc tert-butyloxycarbonyl
- DCE dichloroethane
- DCM dichloromethane
- DIC N,N′-diisopropylcarbodiimide
- DIEA N,N-diisopropylethylamine
- DMF N,N-dimethylformamide
- DTT dithiothreitol
- EDT ethanedithiol
- Fmoc 9-Fluorenylmethyloxycarbonyl
- HATU O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (or N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate N-oxide)
- HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (or N-[(1H-benzotriazol-1-yl)-(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide)
- HCTU (2-(6-chloro-1H-benzotriazole-1-yl)-1, tetramethylaminium hexafluorophosphate) (or N-[(1H-6-chloro-benzotriazol-1-yl)-(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide)
- HOAt 1-hydroxy-7-azabenzotriazole
- HOBt 1-hydroxybenzotriazole
- HPLC high pressure liquid chromatography
- LOD loss on drying
- Mbh 4,4-dimethyloxybenzhydryl
- MBHA 4-methylbenzhydrylamine
- MtBE methyl tert-butyl ether
- Mtr methoxytrimethylbenzene sulfonyl
- OtBu tert-butyl ester
-
Pbf - PEG polyethylene glycol
-
Pmc - TBTU 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (or N-[(1H-benzotriazol-1-yl)-(dimethylamino)methylene]-N-methylmethanaminium tetrafluoroborate N-oxide)
- tBu tert-butyl ether
- TES triethylsilane
- TFA trifluoroacetic acid
- TIPS triisopropylsilane
-
Tmob 2,4,6-trimethoxybenzyl - Trt trityl or triphenylmethyl
- Unless otherwise indicated, the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.
- The term “cleavage cocktail” as used herein refer to a mixture of reagents used to remove, or cleave, the assembled peptide from a resin. In addition, a cleavage cocktail also serves to remove all side chain protecting groups and the N-terminal protecting groups.
- The term “about” (or “approximately”) as used herein in association with parameters or amounts, means that the parameter or amount is within +5% of the stated parameter or amount. For instance, “about 20%” means (20±20*0.05)% which is equal to (20±0.1)%.
- The term “resin,” as used hereafter, refers to either Fmoc-Sieber Amide resin or Sieber Amide resin to which one or more amino acids have been attached.
- The term “room temperature” (or ambient temperature) means a temperature range of from 15-30° C.
- The following example is described for purposes of illustrating a method of the present invention and is not to be construed to limit the present invention in any way.
- The Invention describes a novel method of synthesizing a peptide comprising step-wise solid-phase chemistry.
- In a preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of somatostatin, bombesin, VIP, PACAP, GHRH, glucagon, calcitonin, peptide YY, neuromedin B, PTH, PTHrP, PTH2, GLP-1, Urotensin-II, ghrelin, melanocortin, MIS, LHRH, adropin, GIP, neuropeptide Y, IGF-1, dopamine-somatostatin chimeras, and ACTH.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin or dopamine-somatostatin chimeras.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is selected from an analogue of ghrelin of the formula (I)
-
R1-A1-A2-A3-A4-A5-R2 (I) - wherein
- A1 is Aib, Apc or Inp;
- A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- A3 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- A4 is 2Fua, Orn, 2Pal, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, 3Thi, Thr(Bzl);
- A5 is Apc, Dab, Dap, Lys, Orn, or deleted;
- R1 is hydrogen; and
- R2 is OH or NH;
- provided that
- when A5 is Dab, Dap, Lys, or Orn, then:
-
- A2 is D-Bip, D-Bpa, D-Dip or D-Bal; or
- A3 is D-Bip, D-Bpa, D-Dip or D-BaI; or
- A4 is 2Thi, 3Thi, Taz, 2Fua, 2Pal, 3 Pal, 4Pal, Orn, Thr(Bzl), or Pff;
- when A5 is deleted, then:
-
- A3 is D-Bip, D-Bpa, or D-Dip; or
- A4 is 2Fua, Pff, Taz, or Thr(Bzl); or
- A1 is Apc and -
- A2 is D-Bip, D-Bpa, D-Dip or D-Bal; or
- A3 is D-Bip, D-Bpa, D-Dip or D-Bal; or
- A4 is 2Thi, 3Thi, Orn, 2Pal, 3Pal, or 4Pal;
- and more particularly compound of formula (I) wherein
- A1 is Aib, Ape or lnp;
- A2 is D-Bal, D-Bip, D-Bpa, D-Dip, D-1 Nal, D-2Nal, D-Ser(Bzl), or D-Trp;
- A3 is D-Bal, D-Bpa, D-Dip, D-1 Nal, D-2Nal, or D-Trp;
- A4 is Orn, 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl); and
- A5 is Apc, Lys, or deleted.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of ghrelin of formula (I) as defined above wherein
- A1 is Apc or lnp;
- A2 is D-Bal, D-Bip, D-1 Nal, or D-2Nal;
- A3 is D-Bal, D-1 Nal, D-2Nal, or D-Trp;
- A4 is 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl); and
- A5 is Ape or Lys.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of ghrelin selected from H-Inp-D-Bal-D-Trp-Phe-Apc-NH2, H-Inp-D-2B al-D-Trp-Phe-Apc-NH2, H-Inp-D-Bal-D-Trp-2Thi-Apc-NH2, and H-Inp-D-Bal-D-Trp-Taz-Apc-NH2, and more particularly H-Inp-D-Bal-D-Trp-Phe-Apc-NH2.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras, i.e. a chimeric molecule comprising somatostatin or an analogue thereof and at least one dopamine moiety.
- In a more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras including the structure of Dop A or DopA-Lys(DopA), wherein Lys is L-Lysine, unless expressly designated as D-Lys, A is 1-13, for example Dop1, Dop2, Dop3, Dop4, Dop5, Dop6, Dop7, Dop8, Dop9, Dop10, Dop11, Dop12, Dop13. In another more preferred embodiment, the present invention relates to a process for the synthesis of a therapeutic peptide wherein said peptide is an analogue of dopamine-somatostatin chimeras including the structure of DopA-Lys(DopA), and the compound Dop2-D-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2.
- The general procedure for the synthesis of a fully de-protected therapeutic peptide amide according to the process of the present invention is illustrated below.
- Fmoc-Sieber Amide resin (Merck Chemicals, Darmstadt, Germany) is initially swelled using 1 to 3 treatments of 7 to 12 vols, 10 vols preferred, of DMF (Samsung, Korea), in addition, for up to 1 hour, although 3 treatments lasting about 10-30 minutes each are preferred.
- Fmoc de-protection of the Sieber Amide resin is accomplished using 1 to 2 treatments of a solution of piperidine in DMF (about 10-20% v/v, 15% v/v preferred) lasting 5 to 20 minutes, although 2 treatments lasting 10 minutes each are preferred.
- The de-protected resin is washed 3 to 5 times with 7 to 12 vols of DMF lasting for up to 5 minutes, although 3 washes of 10 vols of DMF lasting up to 5 minutes for each wash is preferred.
- The Fmoc-amino acids are activated for coupling to the resin by dissolving the Fmoc-amino acid together with the coupling reagent(s) in DMF, adding a base such as DIEA (SAFC, Gillingham, United Kingdom), stirring for up to 5 minutes (1-2 minutes preferred), and charging to the resin in the reactor.
- Fmoc-amino acid coupling are carried out using about 1.2 to 2.0 mol equivs (1.5 mol equivs preferred) of Fmoc-amino acid relative to the resin using HCTU (Merck Chemicals) or TBTU/HOBt (0.5 to 2.0 mol equivs relative to the Fmoc amino acid) (both TBTU and HOBt obtained from SAFC) with a base, preferably DIEA (about 1.5 to 3.5 mol equivs relative to the Fmoc-amino acid, although specific equivs are preferred for particular amino acids), in DMF (4 to 10 vols, 5 to 7 vols preferred) lasting 30 to 120 minutes (although duration varies depending on the amino acid being coupled, however, 60 minutes is preferred for most amino acids) at an ambient temperature (preferably 15 to 30° C.). Either HCTU (1.2 equivs relative to the Fmoc-amino acid) or TBTU with HOBt (0.98 mol equivs) are preferred depending on the amino acid being coupled.
- After each Fmoc-amino acid coupling, the resin is washed 2 to 4 times with 7 to 12 vols of DMF (2 washed of 10 vols of DMF is preferred) each washing lasting up to 5 minutes.
- The desired peptide is cleaved from the resin and any side chain protecting groups are “de-protected” using a cleavage cocktail consisting of about 15 to 25% v/v TFA (Rhodia, Lyon, France) (although preferably 15 to 20% v/v, and approximately 20% v/v is more preferred) with about 2.5 to 12% v/v TIPS (SAFC, Gillingham, United Kingdom) (although preferably 5-10% v/v, and about 10% v/v is more preferred) used as a scavenger with the remainder of the cleavage cocktail comprising 62.5 to 82.5% v/v DCM (INEOS Chlor, Runcorn, UK) (depending on the percentage of TFA and TIPS used). The resin is immersed in and agitated with the cleavage cocktail for 2 to 3 hours (2.5 hours preferred) at about ambient temperature (about 15 to 30° C.). Intermittent sparging with nitrogen gas or blanketing the cleavage reaction mixture with nitrogen gas is introduced. The cleavage mixture containing the desired peptide and the “spent” resin is filtered. The “spent” resin is washed with a small volume of either fresh cleavage cocktail or a TFA/DCM (15-20:80-85 v/v) mixture (1 to 2 times using 1 to 2 vol over resin weight). An optional wash of a small volume of MeOH (1 to 2 times using about 1 to 2 vol over resin weight) (Univar, Dublin, Ireland) may follow.
- The peptide-rich filtrates are combined and evaporated to <20% of the original filtrate weight (<15% preferred). The crude peptide is precipitated from the concentrated solution by an organic anti-solvent such as MtBE (Univar, Dublin, Ireland) (about 5 to 15 vols, preferably 6.5 to 10 vols), filtered, and washed with small volumes of the same organic anti-solvent (up to 3 times with about 1 to 2 vols). The precipitated peptide may be dried. Dissolution of the dry or semi-wet peptide precipitate for subsequent purification is carried out using a dilute acid such as acetic acid together with an organic solvent such as ACN (INEOS Nitriles, Rolle, Switzerland) (about % v/v depending on the solubility of the peptide and the % at which it elutes during chromatographic purification).
- Purification of the peptide to a very high purity (>99%) combined with salt exchange (e.g. from TFA to acetate salt) is achievable by reverse phase preparative HPLC (on C18 or C8 silica, or other suitable packing) to those skilled in the art. Isolation of the purified peptide by lyophilisation or other methods of isolating a peptide powder from solution (e.g. spray-drying, precipitation or crystallization followed by drying) are possible to those skilled in the art.
- In the synthesis of chimeric compounds such as dopamine-somatostatin chimeras, the process includes additional steps. The general procedure of these additional steps may be illustrated as follows: before step (i),
-
- Step h-1: a dopamine is activated for coupling by dissolution in HCTU and HOBt in DMF;
- Step h-2:—a base is added to the solution of step (h-1);
- Step h-3: the solution of step (h-2) is agitated for 1 minute then said resin is stirred for about 1.5 hours;
- Step h-4: the resulting resin is washed with DMF; and
- Step h-5: the resin is further washed with 1-3 vols MeOH.
- A mixture of TFA, TIPS and DCM is used to cleave the peptide from the resin and simultaneously remove the side chain protecting groups from the amino acids, and preferably the ratio of TFA:TIPS:DCM is 15:5:80. Then the precipitate is washed with MtBE. Finally, the precipitate is cyclized.
- (as described in International Patent Application WO 2004/014415 which is incorporated by reference in its entirety herein). In the process as described below, all equivalents are relative to the resin-batch scale.
- The titled peptide was synthesized in a 50-liter filter reactor (Buchi, Flawil, Switzerland.
- The synthesis was carried out on a 1.04 mole scale (1.4 kg input resin).
- Approximately, 1.41 kg. of Fmoc-Sieber Amide resin was swelled with DMF (3
times 10 vol). The Fmoc group was de-protected by two treatments of a 15% v/v solution of piperidine (BASF, Schwarheide, Germany) in DMF (2×10 vols, 10 minutes each). The resin was then washed with DMF (3×10 vols). - Some of the Fmoc amino acids employed (Apc, D-Trp) required Boc-protected side chains, the others (Phe, D-Bal, Inp) did not require side chain protection.
- Introduced into the reactor was a solution of 1.5 equivalents of Fmoc-Apc(Boc)-OH, pre-activated with 1.8 equivalents of HCTU and 3 equivalents of DIEA in DMF (6 vol). The solution and resin were stirred for approximately 90 minutes. The resin was drained and washed with DMF (2×10 vol). The Fmoc group was de-protected as outlined above and the second amino acid, Fmoc-Phe-OH, was coupled using the same conditions as outlined for Fmoc-Apc(Boc)-OH. The cycle of Fmoc de-protection, washing and Fmoc-amino acid coupling and washing was repeated for Fmoc-D-Trp(Boc)-OH, Fmoc-D-Bal-OH and Fmoc-Inp-OH with the Fmoc-amino acid coupling steps utilizing 1.45 equivalents of TBTU, 1.45 equivs of HOBt, and 2.25 equivs of DIEA in DMF (6-7 vol). Coupling times were 60 minutes.
- Upon completion of the peptide assembly on the Sieber Amide resin, the resin was washed with DMF and then further washed twice with 10 liters of methanol and dried
- The peptide was cleaved from the resin and its side chain-protecting groups removed using 10 vol. of a cleavage cocktail comprised of TFA/TIPS/DCM (20/10/70% v/v) for 2.5 hours. The peptide-containing filtrate was evaporated under reduced pressure, precipitated and washed with MtBE before being dissolved in dilute acetic acid and acetonitrile for subsequent purification. The synthesis yield was 80.8%, purity by HPLC 90.0%.
- The peptide was purified using a reverse-phase preparative HPLC column (Novasep, Pompey, France) packed with C18 stationary phase (EKA Chemicals AB, Bohus, Sweden). Purification and salt exchange was performed under gradient elution using ammonium acetate and acetic acid buffers with acetonitrile as organic modifier.
-
- (i.e. Dop2-D-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 as described in International Patent Application WO 2004/091490 which is incorporated by reference in its entirety herein).
- In the process as described below, all equivalents are relative to the resin-batch scale.
- The titled peptide was synthesized in a 50-liter filter.
- The synthesis was carried out on a 0.72 mole scale (1.2 kg input resin).
- The protected amino acids employed herein can be obtained from Synthetech, Inc., Albany, Oreg., USA or Senn Chemicals, Dielsdorf, Switzerland
- About 1.2 kg of Fmoc-Sieber Amide resin was swelled with DMF (3×10 vol) in the reactor and the Fmoc group was de-protected using two treatments of a 15% v/v solution of piperidine in DMF (10 vols per treatment lasting 10 minutes in duration). The resin was washed with DMF (4×10 vols).
- The first amino acid to be coupled to the resin, Fmoc-Thr(tBu)—OH (2.0 equivs.), TBTU (1.96 equivs), HOBt (1.96 equivs), and DIEA (3.0 equivs in DMF (5.5 vol)) were stirred with the resin for 60 minutes. The resin was drained and Fmoc-Thr(tBu)—OH was re-coupled using Fmoc-Thr(tBu)—OH (1.0 equivs), TBTU (0.98 equivs), HOBt (0.98 equivs) and DIEA (1.5 equivs) in DMF (2.8 vol) for 60 minutes.
- The resin was washed with DMF (4×10 vols).
- The Fmoc group was de-protected as outlined above and the second aminoacid, Fmoc-Cys(Acm)-OH, was coupled using the same conditions as outlined for Fmoc-Thr(tBu)—OH. The cycle of Fmoc de-protection, washing, Fmoc-amino acid coupling and washing was repeated for Fmoc-Abu-OH, Fmoc-Lys(Boc)-OH, Fmoc-D-Trp(Boc)-OH, Fmoc-Tyr(tBu)—OH, Fmoc-Cys(Acm)-OH and Fmoc-D-Lys(Fmoc)-OH in that order. The Fmoc-amino acid coupling steps were performed using TBTU (1.96 equivs), HOBt (1.96 equivs) and DIEA (3.0 equivs) in DMF (5.8-7 vol) for 60 minutes.
- The dopamine portion of the titled molecule, i.e.
- (Biomeasure, Inc., Milford, Mass., USA) was activated for coupling by dissolving it (2.75 molar equivs relative to resin), HCTU (2.79 eq.) and HOBt (3.3 eq.) in DMF (12.3 vols per gram of resin), adding DIEA (6.27 eq.) and agitating for 1 minute before stirring with the resin for 1.5 hours.
- After final washing of the peptidyl resin with DMF, the resin was further washed with MeOH (2×10 vol) and dried.
- Cleavage of the peptide chimera from the resin and removal of the side chain protecting groups was effected in one pot using TFA:TIPS:DCM (15:5:80, 12 vol, 34.3 L) for 2.0 hours. Intermittent sparging of the cleavage reaction mixture with nitrogen gas was used (for a duration of 1-2 minutes every 30 minutes). After filtration of the cleavage mixture (which contains the desired peptide) from the resin, the “spent” resin was washed with TFA/DCM (15:85) mixture (1.3 vol over resin weight, 3 times). The peptide-rich filtrates were combined and evaporated to 10.4% (6.2 Kg) of original filtrate weight. The crude peptide was precipitated from the concentrated solution by addition to stirred MtBE (6.5 vols over residual weight post evaporation, 40 L), filtered, and washed with MtBE (1 vol over residual weight post evaporation, 6.2 L, once). Dissolution of the semi-dry peptide precipitate for subsequent cyclisation was carried out using 38 vol (45 L) over resin weight of 0.1% v/v TFA/water, with ACN (30% v/v).
- The synthesis/cleavage yield was 72.6%, purity by HPLC was 79.1%.
- Examples of therapeutic peptides which can be synthesized using the novel process described herein, include, but are not limited to, the following:
-
H-Inp-D-1-Nal-D-Trp-3-Pal-Lys-NH2 H-Inp-D-2-Nal-D-Trp-4-Pal-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Orn-Lys-NH2 H-Inp-D-Bip-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Dip-D-Trp-Phe-Lys-NH2 H-Inp-D-Bpa-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Bpa-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Trp-3-Pal-NH2 H-Inp-D-2-Nal-D-Trp-4-Pal-NH2 H-Inp-D-1-Nal-D-Trp-3-Pal-NH2 H-Inp-D-Bip-D-Trp-Phe-NH2 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-NH2 H-Inp-D-2-Nal-D-Trp-Pff-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-NH2 H-Inp-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-Dip-D-Trp-Phe-NH2 H-Inp-D-2-Nal-D-Dip-Phe-NH2 H-Inp-D-Bal-D-Trp-Phe-NH2 H-Inp-D-2-Nal-D-Bal-Phe-NH2 H-Inp-D-2-Nal-D-Trp-3-Pal-Lys-NH2 H-Inp-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Phe-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Phe-Apc-NH2 H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Thi-NH2 H-Apc-D-1-Nal-D-Trp-Phe-NH2 H-Inp-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Bal-D-Trp-Taz-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Phe-Apc-NH2 H-Apc-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-1-Nal-D-1-Nal-Phe-Apc-NH2 H-Apc-D-1-Nal-D-2-Nal-Phe-Apc-NH2 H-Apc-D-1-Nal-D-1-Nal-Phe-Lys-NH2 H-Apc-D-Bal-D-1-Nal-Phe-Apc-NH2 H-Apc-D-Bal-D-2-Nal-Phe-Apc-NH2 H-Apc-D-Bal-D-1-Nal-Phe-Lys-NH2 H-Apc-D-Bal-D-2-Nal-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-NH2 H-Apc-D-Bal-D-Trp-Phe-NH2 H-Apc-D-1-Nal-D-Trp-Taz-NH2 H-Apc-D-Bal-D-Trp-2-Thi-NH2 H-Apc-D-Bal-D-Trp-Taz-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-NH2 H-Apc-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-1-Nal-D-Trp-Taz-Apc-NH2 H-Inp-D-Bal-D-Trp-Taz-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Taz-Apc-NH2 H-Apc-D-Bal-D-Trp-Taz-Apc-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-NH2 H-Apc-D-1-Nal-D-Trp-2-Pal-NH2 H-Apc-D-1-Nal-D-Trp-3-Pal-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-NH2 H-Apc-D-1-Nal-D-Trp-4-Pal-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Pff-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-NH2 H-Apc-D-2-Nal-D-Trp-2-Pal-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-3-Pal-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-NH2 H-Apc-D-2-Nal-D-Trp-4-Pal-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Pff-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Fua-NH2 H-Apc-D-Bal-D-Bal-2-Pal-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Thi-NH2 H-Apc-D-Bal-D-Bal-3-Pal-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Lys-NH2 H-Apc-D-Bal-D-Bal-3-Thi-NH2 H-Apc-D-Bal-D-Bal-4-Pal-NH2 H-Apc-D-Bal-D-Bal-Pff-Apc-NH2 H-Apc-D-Bal-D-Bal-Pff-Lys-NH2 H-Apc-D-Bal-D-Bal-Pff-NH2 H-Apc-D-Bal-D-Bal-Phe-Apc-NH2 H-Apc-D-Bal-D-Bal-Phe-Lys-NH2 H-Apc-D-Bal-D-Bal-Phe-NH2 H-Apc-D-Bal-D-Bal-Taz-Apc-NH2 H-Apc-D-Bal-D-Bal-Taz-Lys-NH2 H-Apc-D-Bal-D-Bal-Taz-NH2 H-Apc-D-Bal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Fua-NH2 H-Apc-D-Bal-D-Trp-2-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-3-Thi-NH2 H-Apc-D-Bal-D-Trp-4-Pal-NH2 H-Apc-D-Bal-D-Trp-Pff-Apc-NH2 H-Apc-D-Bal-D-Trp-Pff-Lys-NH2 H-Apc-D-Bal-D-Trp-Pff-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-NH2 H-Inp-D-1-Nal-D-Bal-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Pff-NH2 H-Inp-D-1-Nal-D-Bal-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Pff-NH2 H-Inp-D-1-Nal-D-Trp-Taz-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-NH2 H-Inp-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-2-Nal-D-Trp-Pff-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Inp-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-Bal-D-Bal-2-Fua-Lys-NH2 H-Inp-D-Bal-D-Bal-2-Fua-NH2 H-Inp-D-Bal-D-Bal-2-Thi-Lys-NH2 H-Inp-D-Bal-D-Bal-3-Thi-Lys-NH2 H-Inp-D-Bal-D-Bal-Pff-Lys-NH2 H-Inp-D-Bal-D-Bal-Pff-NH2 H-Inp-D-Bal-D-Bal-Phe-Lys-NH2 H-Inp-D-Bal-D-Bal-Taz-Lys-NH2 H-Inp-D-Bal-D-Bal-Taz-NH2 H-Inp-D-Bal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-Bal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-Bal-D-Trp-2-Fua-NH2 H-Inp-D-Bal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-Bal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-Pff-Apc-NH2 H-Inp-D-Bal-D-Trp-Pff-Lys-NH2 H-Inp-D-Bal-D-Trp-Pff-NH2 H-Inp-D-Bal-D-Trp-Taz-NH2 H-Inp-D-Bip-D-Bal-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Bal-2-Fua-NH2 H-Inp-D-Bip-D-Bal-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-Pff-Lys-NH2 H-Inp-D-Bip-D-Bal-Pff-NH2 H-Inp-D-Bip-D-Bal-Taz-Lys-NH2 H-Inp-D-Bip-D-Bal-Taz-NH2 H-Inp-D-Bip-D-Trp-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Trp-2-Fua-NH2 H-Inp-D-Bip-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-Pff-Lys-NH2 H-Inp-D-Bip-D-Trp-Pff-NH2 H-Inp-D-Bip-D-Trp-Taz-Lys-NH2 H-Inp-D-Bip-D-Trp-Taz-NH2 H-Inp-D-1-Nal-D-Trp-3-Pal-Lys-NH2 H-Inp-D-2-Nal-D-Trp-4-Pal-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Orn-Lys-NH2 H-Inp-D-Bip-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Dip-D-Trp-Phe-Lys-NH2 H-Inp-D-Bpa-D-Trp-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Bpa-Phe-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Thr(Bzl)-NH2 H-Inp-D-2-Nal-D-Trp-Pff-NH2 H-Inp-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-2-Nal-D-Dip-Phe-NH2 H-Inp-D-2-Nal-D-Trp-3-Pal-Lys-NH2 H-Inp-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-2-Nal-D-Trp-Phe-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Phe-Apc-NH2 H-Inp-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Inp-D-Bal-D-Trp-Taz-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-Taz-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Phe-Apc-NH2 H-Apc-D-Bal-D-Trp-Phe-Apc-NH2 H-Apc-D-1-Nal-D-1-Nal-Phe-Apc-NH2 H-Apc-D-1-Nal-D-2-Nal-Phe-Apc-NH2 H-Apc-D-1-Nal-D-1-Nal-Phe-Lys-NH2 H-Apc-D-Bal-D-1-Nal-Phe-Apc-NH2 H-Apc-D-Bal-D-2-Nal-Phe-Apc-NH2 H-Apc-D-Bal-D-1-Nal-Phe-Lys-NH2 H-Apc-D-Bal-D-2-Nal-Phe-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-NH2 H-Apc-D-Bal-D-Trp-Phe-NH2 H-Apc-D-1-Nal-D-Trp-Taz-NH2 H-Apc-D-Bal-D-Trp-2-Thi-NH2 H-Apc-D-Bal-D-Trp-Taz-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-NH2 H-Apc-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-1-Nal-D-Trp-Taz-Apc-NH2 H-Inp-D-Bal-D-Trp-Taz-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Taz-Apc-NH2 H-Apc-D-Bal-D-Trp-Taz-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-Bal-D-Trp-Pff-Lys-NH2 H-Inp-D-Bal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-Bal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-Bal-D-Trp-Pff-Apc-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-Bal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Trp-Pff-Lys-NH2 H-Inp-D-Bal-D-Bal-Phe-Lys-NH2 H-Inp-D-Bal-D-Bal-2-Thi-Lys-NH2 H-Inp-D-Bal-D-Bal-3-Thi-Lys-NH2 H-Inp-D-Bal-D-Bal-Taz-Lys-NH2 H-Inp-D-Bal-D-Bal-2-Fua-Lys-NH2 H-Inp-D-Bal-D-Bal-Pff-Lys-NH2 H-Apc-D-Bal-D-Bal-Phe-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Lys-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Lys-NH2 H-Apc-D-Bal-D-Bal-Taz-Lys-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Lys-NH2 H-Apc-D-Bal-D-Bal-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Phe-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-3-Thi-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Taz-Lys-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-Lys-NH2 H-Inp-D-1-Nal-D-Bal-Pff-Lys-NH2 H-Inp-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Inp-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Lys-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Lys-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-Lys-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Lys-NH2 H-Inp-D-Bip-D-Trp-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Trp-Taz-Lys-NH2 H-Inp-D-Bip-D-Trp-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Trp-Pff-Lys-NH2 H-Inp-D-Bip-D-Bal-2-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-3-Thi-Lys-NH2 H-Inp-D-Bip-D-Bal-Taz-Lys-NH2 H-Inp-D-Bip-D-Bal-2-Fua-Lys-NH2 H-Inp-D-Bip-D-Bal-Pff-Lys-NH2 H-Apc-D-Bal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Trp-Pff-Apc-NH2 H-Apc-D-Bal-D-Bal-Phe-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-3-Thi-Apc-NH2 H-Apc-D-Bal-D-Bal-Taz-Apc-NH2 H-Apc-D-Bal-D-Bal-2-Fua-Apc-NH2 H-Apc-D-Bal-D-Bal-Pff-Apc-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-1-Nal-D-Trp-Pff-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Taz-Apc-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-Apc-NH2 H-Apc-D-2-Nal-D-Trp-Pff-Apc-NH2 H-Inp-D-Bal-D-Trp-Taz-NH2 H-Inp-D-Bal-D-Trp-2-Fua-NH2 H-Inp-D-Bal-D-Trp-Pff-NH2 H-Apc-D-Bal-D-Trp-3-Thi-NH2 H-Apc-D-Bal-D-Trp-2-Fua-NH2 H-Apc-D-Bal-D-Trp-Pff-NH2 H-Apc-D-Bal-D-Trp-4-Pal-NH2 H-Apc-D-Bal-D-Trp-3-Pal-NH2 H-Apc-D-Bal-D-Trp-2-Pal-NH2 H-Inp-D-Bal-D-Bal-Taz-NH2 H-Inp-D-Bal-D-Bal-2-Fua-NH2 H-Inp-D-Bal-D-Bal-Pff-NH2 H-Apc-D-Bal-D-Bal-Phe-NH2 H-Apc-D-Bal-D-Bal-2-Thi-NH2 H-Apc-D-Bal-D-Bal-3-Thi-NH2 H-Apc-D-Bal-D-Bal-Taz-NH2 H-Apc-D-Bal-D-Bal-2-Fua-NH2 H-Apc-D-Bal-D-Bal-Pff-NH2 H-Apc-D-Bal-D-Bal-4-Pal-NH2 H-Apc-D-Bal-D-Bal-3-Pal-NH2 H-Apc-D-Bal-D-Bal-2-Pal-NH2 H-Inp-D-1-Nal-D-Trp-Taz-NH2 H-Inp-D-1-Nal-D-Trp-2-Fua-NH2 H-Inp-D-1-Nal-D-Trp-Pff-NH2 H-Inp-D-1-Nal-D-Bal-Taz-NH2 H-Inp-D-1-Nal-D-Bal-2-Fua-NH2 H-Inp-D-1-Nal-D-Bal-Pff-NH2 H-Inp-D-2-Nal-D-Trp-Taz-NH2 H-Inp-D-2-Nal-D-Trp-2-Fua-NH2 H-Inp-D-2-Nal-D-Trp-Pff-NH2 H-Apc-D-1-Nal-D-Trp-3-Thi-NH2 H-Apc-D-1-Nal-D-Trp-2-Fua-NH2 H-Apc-D-1-Nal-D-Trp-Pff-NH2 H-Apc-D-1-Nal-D-Trp-4-Pal-NH2 H-Apc-D-1-Nal-D-Trp-3-Pal-NH2 H-Apc-D-1-Nal-D-Trp-2-Pal-NH2 H-Apc-D-2-Nal-D-Trp-3-Thi-NH2 H-Apc-D-2-Nal-D-Trp-2-Fua-NH2 H-Apc-D-2-Nal-D-Trp-Pff-NH2 H-Apc-D-2-Nal-D-Trp-4-Pal-NH2 H-Apc-D-2-Nal-D-Trp-3-Pal-NH2 H-Apc-D-2-Nal-D-Trp-2-Pal-NH2 H-Inp-D-Bip-D-Trp-Taz-NH2 H-Inp-D-Bip-D-Trp-2-Fua-NH2 H-Inp-D-Bip-D-Trp-Pff-NH2; H-Inp-D-Bip-D-Bal-Taz-NH2 H-Inp-D-Bip-D-Bal-2-Fua-NH2 H-Inp-D-Bip-D-Bal-Pff-NH2 H-Inp-D-1-Nal-D-Trp-2-Thi-Apc-NH2 H-Inp-D-Bal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-1-Nal-D-Trp-2-Thi-Apc-NH2 H-Apc-D-Bal-D-Trp-2-Thi-Apc-NH2 and H-Apc-D-1-Nal-D-Trp-Phe-Lys-NH2. - Dopamine-somatostatin chimeras that may be synthesized using the claimed method, include but are not limited to, those molecules as described in WO 02/100888 and WO 04/091490, as follows:
-
Dop2-D-Phe-Doc-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Ac-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Ac-D-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop2-Lys(Ac)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop2-D-Lys(Ac)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop3-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop4-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop3-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop4-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop5-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop6-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop7-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop8-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop9-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop10-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop11-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop12-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop13-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop5-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop6-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop7-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop8-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop9-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop10-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop11-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop12-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop13-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr-NH2 Dop5-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop6-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop7-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop8-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop9-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop10-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop11-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop12-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop13-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop5-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop6-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop7-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop8-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop9-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop10-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop11-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop12-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop13-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH2 Dop5-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop6-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop7-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop8-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop9-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop10-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop11-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop12-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop13-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop5-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop6-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop7-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop8-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop9-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop10-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop11-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop12-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop13-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal-NH2 Dop1-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop2-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop1-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop2-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop3-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop4-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop3-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop4-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop5-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop6-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop7-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop8-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop9-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop10-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop11-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop12-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop13-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop3-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop4-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop5-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop6-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop7-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop8-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop9-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop10-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop11-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop12-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop13-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop1-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop2-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop3-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop4-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop1-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop2-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop3-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop4-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop5-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop6-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop7-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop8-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop9-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr(Bzl)- Tyr-NH2 Dop10-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop11-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop12-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop13-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D-Cys]-Thr (Bzl)-Tyr-NH2 Dop1-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop2-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop3-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop4-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop1-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser (Bzl)-Tyr-NH2 Dop2-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser (Bzl)-Tyr-NH2 Dop3-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser (Bzl)-Tyr-NH2 Dop4-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser (Bzl)-Tyr-NH2 Dop5-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop6-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop7-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop8-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop9-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop10-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop11-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop12-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop13-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]-Ser(Bzl)- Tyr-NH2 Dop5-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop6-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop7-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop8-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop9-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop10-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop11-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop12-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop13-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe-Cys]-NH2 Dop5-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop6-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop7-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop8-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop9-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr- NH2 Dop10-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop11-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop12-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop13-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop5-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop6-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop7-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop8-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop9-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop10-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop11-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop12-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop13-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]-Thr-NH2 Dop2-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop2-D-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop1-Lys(Dop1)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop1-Lys(Dop1)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop1-D-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop1-Lys(Dop1)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop1-Lys(Dop1)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop1-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop1-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop1-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop1-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop2-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop2-D-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop2-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop2-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop2-Lys(Dop2)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop3-Lys(Dop3)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop3-Lys(Dop3)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop3-Lys(Dop3)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop3-Lys(Dop3)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop3-Lys(Dop3)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop3-D-Lys(Dop3)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop3-D-Lys(Dop3)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop3-D-Lys(Dop3)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop3-D-Lys(Dop3)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop3-D-Lys(Dop3)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop3-Lys(Dop3)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop3-Lys(Dop3)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop3-Lys(Dop3)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop3-Lys(Dop3)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop3-Lys(Dop3)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop3-Lys(Dop3)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop3-Lys(Dop3)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop3-Lys(Dop3)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop3-Lys(Dop3)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop3-Lys(Dop3)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop3-Lys(Dop3)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop3-Lys(Dop3)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop4-Lys(Dop4)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop4-Lys(Dop4)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop4-Lys(Dop4)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop4-Lys(Dop4)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop4-Lys(Dop4)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop4-D-Lys(Dop4)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop4-D-Lys(Dop4)-Aepa-D-Phe-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop4-D-Lys(Dop4)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop4-D-Lys(Dop4)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop4-D-Lys(Dop4)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop4-Lys(Dop4)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop4-Lys(Dop4)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop4-Lys(Dop4)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop4-Lys(Dop4)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop4-Lys(Dop4)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop4-Lys(Dop4)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop4-Lys(Dop4)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop4-Lys(Dop4)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop4-Lys(Dop4)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop4-Lys(Dop4)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop4-Lys(Dop4)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop4-Lys(Dop4)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop5-Lys(Dop5)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop5-D-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop5-Lys(Dop5)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2Nal-NH2 Dop5-Lys(Dop5)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2Nal- NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop5-Lys(Dop5)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop6-Lys(Dop6)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop6-Lys(Dop6)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop6-Lys(Dop6)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop6-Lys(Dop6)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop6-D-Lys(Dop6)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop6-D-Lys(Dop6)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop6-D-Lys(Dop6)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop6-D-Lys(Dop6)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop6-Lys(Dop6)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop6-Lys(Dop6)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop6-Lys(Dop6)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop6-Lys(Dop6)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop6-Lys(Dop6)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop6-Lys(Dop6)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop6-Lys(Dop6)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Thr-Cys]-2-Nal-NH2 Dop6-Lys(Dop6)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Thr-Cys]-2-Nal-NH2 Dop6-Lys(Dop6)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop6-Lys(Dop6)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop6-Lys(Dop6)-Lys-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp- Lys-Val-Cys]-Trp-NH2 Dop6-Lys(Dop6)-D-Tyr-D-Tyr-c[Cys-Tyr-D-Trp-Lys- Val-Cys]-Trp-NH2 Dop7-Lys(Dop7)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop7-Lys(Dop7)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop7-D-Lys(Dop7)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop7-D-Lys(Dop7)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop7-Lys(Dop7)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop7-Lys(Dop7)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop7-Lys(Dop7)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop7-Lys(Dop7)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop7-Lys(Dop7)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop7-Lys(Dop7)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop8-Lys(Dop8)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop8-Lys(Dop8)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop8-D-Lys(Dop8)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop8-D-Lys(Dop8)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop8-Lys(Dop8)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop8-Lys(Dop8)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop8-Lys(Dop8)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop8-Lys(Dop8)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop8-Lys(Dop8)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop8-Lys(Dop8)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop9-Lys(Dop9)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop9-Lys(Dop9)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop9-D-Lys(Dop9)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop9-D-Lys(Dop9)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop9-Lys(Dop9)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop9-Lys(Dop9)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop9-Lys(Dop9)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]- 2-Nal-NH2 Dop9-Lys(Dop9)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2-Nal- NH2 Dop9-Lys(Dop9)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val-Cys]- Trp-NH2 Dop9-Lys(Dop9)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop10-Lys(Dop10)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop10-Lys(Dop10)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop10-D-Lys(Dop10)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop10-D-Lys(Dop10)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop10-Lys(Dop10)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop10-Lys(Dop10)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop10-Lys(Dop10)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr- Cys]-2-Nal-NH2 Dop10-Lys(Dop10)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2- Nal-NH2 Dop10-Lys(Dop10)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop10-Lys(Dop10)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop11-Lys(Dop11)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop11-Lys(Dop11)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop11-D-Lys(Dop11)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop11-D-Lys(Dop11)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop11-Lys(Dop11)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop11-Lys(Dop11)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop11-Lys(Dop11)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr- Cys]-2-Nal-NH2 Dop11-Lys(Dop11)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2- Nal-NH2 Dop11-Lys(Dop11)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop11-Lys(Dop11)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop12-Lys(Dop12)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop12-Lys(Dop12)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop12-D-Lys(Dop12)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop12-D-Lys(Dop12)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop12-Lys(Dop12)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop12-Lys(Dop12)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop12-Lys(Dop12)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr- Cys]-2-Nal-NH2 Dop12-Lys(Dop12)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2- Nal-NH2 Dop12-Lys(Dop12)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop12-Lys(Dop12)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop13-Lys(Dop13)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop13-Lys(Dop13)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]-Thr- NH2 Dop13-D-Lys(Dop10)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop13-D-Lys(Dop13)-c[Cys-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop13-Lys(Dop13)-D-2-Nal-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop13-Lys(Dop13)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr- NH2 Dop13-Lys(Dop13)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Thr- Cys]-2-Nal-NH2 Dop13-Lys(Dop13)-c[Cys-Tyr-D-Trp-Lys-Thr-Cys]-2- Nal-NH2 Dop13-Lys(Dop13)-D-Phe-c[Cys-Tyr-D-Trp-Lys-Val- Cys]-Trp-NH2 Dop13-Lys(Dop13)-c[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp- NH2 Dop1-Lys(Dop1)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys- D-Cys]-Ser(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D- Trp-Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop1-D-Lys(Dop1)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys- D-Cys]-Ser(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop2-Lys(Dop2)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D- Trp-Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop2-D-Lys(Dop2)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop3-Lys(Dop3)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop3-D-Lys(Dop3)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys- D-Cys]-Ser(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop4-Lys(Dop4)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Aepa-Caeg-c[D-Cys-3-Pal-D-Trp- Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Aepa-Caeg-c[D-Cys-Phe-D-Trp-Lys- D-Cys]-Ser(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Lys-Aepa-Caeg-c[D-Cys-3-Pal-D- Trp-Lys-D-Cys]-Thr(Bzl)-Tyr-NH2 Dop4-D-Lys(Dop4)-Lys-Aepa-Caeg-c[D-Cys-Phe-D-Trp- Lys-D-Cys]-Ser(Bzl)-Tyr-NH2 Dop5-Lys(Dop5)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop5-Lys(Dop5)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop5-D-Lys(Dop5)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop5-D-Lys(Dop5)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop5-Lys(Dop5)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop5-Lys(Dop5)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop5-D-Lys(Dop5)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop5-D-Lys(Dop5)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop6-Lys(Dop6)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop6-Lys(Dop6)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop6-D-Lys(Dop6)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop6-D-Lys(Dop6)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop6-Lys(Dop6)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop6-Lys(Dop6)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop6-D-Lys(Dop6)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop6-D-Lys(Dop6)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop7-Lys(Dop7)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop7-Lys(Dop7)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop7-Lys(Dop7)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop7-Lys(Dop7)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop8-Lys(Dop8)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop8-Lys(Dop8)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop8-Lys(Dop8)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop8-Lys(Dop8)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop9-Lys(Dop9)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop9-Lys(Dop9)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D-Cys]- Ser(Bzl)-Tyr-NH2 Dop9-Lys(Dop9)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop9-Lys(Dop9)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop10-Lys(Dop10)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop10-Lys(Dop10)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop10-Lys(Dop10)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop10-Lys(Dop10)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop11-Lys(Dop11)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop11-Lys(Dop11)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop11-Lys(Dop11)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop11-Lys(Dop11)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop12-Lys(Dop12)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop12-Lys(Dop12)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop12-Lys(Dop12)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop12-Lys(Dop12)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop13-Lys(Dop13)-Caeg-c[D-Cys-3-Pal-D-Trp-Lys-D- Cys]-Thr(Bzl)-Tyr-NH2 Dop13-Lys(Dop13)-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop13-Lys(Dop13)-Lys-Caeg-c[D-Cys-3-Pal-D-Trp-Lys- D-Cys]-Thr(Bzl)-Tyr-NH2 Dop13-Lys(Dop13)-Lys-Caeg-c[D-Cys-Phe-D-Trp-Lys-D- Cys]-Ser(Bzl)-Tyr-NH2 Dop1-Lys(Dop1)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop1-D-Lys(Dop1)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop1-Lys(Dop1)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop2-Lys(Dop2)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop2-Lys(Dop2)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop3-Lys(Dop3)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop3-Lys(Dop3)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop3-Lys(Dop3)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop4-Lys(Dop4)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop4-Lys(Dop4)-D-Phe-c-[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop4-Lys(Dop4)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop5-Lys(Dop5)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop5-D-Lys(Dop5)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop5-Lys(Dop5)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop6-Lys(Dop6)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop6-Lys(Dop6)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop6-D-Lys(Dop6)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop6-D-Lys(Dop6)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop6-Lys(Dop6)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop6-D-Lys(Dop6)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop7-Lys(Dop7)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop7-Lys(Dop7)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop7-Lys(Dop7)-c[Cys-Phe-(N-Me)D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop8-Lys(Dop8)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop8-Lys(Dop8)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop9-Lys(Dop9)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop9-Lys(Dop9)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop10-Lys(Dop10)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop10-Lys(Dop10)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop11-Lys(Dop11)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop11-Lys(Dop11)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop12-Lys(Dop12)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop12-Lys(Dop12)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop13-Lys(Dop13)-c[Cys-Phe-Phe-D-Trp-Lys-Thr-Phe- Cys]-NH2 Dop13-Lys(Dop13)-D-Phe-c[Cys-Phe-(N-Me)D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop1-D-Phe-c[Cys-3-I-Tyr(Dop1)-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop1-D-Phe-Doc-D-Phe-c[Cys-3-I-Tyr(Dop1)-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop1-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop1-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop1-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop1-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop1-Lys(Dop1)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop1-Lys(Dop1)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop1-Lys(Dop1)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop1-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop1-D-Lys(Dop1)-Lys-D-Tyr-D-Tyr-c[Cys-34-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop2-D-Phe-c[Cys-3-I-Tyr(Dop2)-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop2-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop2-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop2-Lys(Dop2)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop2-Lys(Dop2)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop2-Lys(Dop2)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop2-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop2-D-Lys(Dop2)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop3-Lys(Dop3)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop4-Lys(Dop4)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop3-Lys(Dop3)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop4-Lys(Dop4)-Aepa-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop5-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Thr-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Thr-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Abu-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Abu- Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop5-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Abu-Cys]- Thr-NH2 Dop5-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Abu-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Abu-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Val-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop5-Lys(Dop5)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Val- Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 Dop5-Lys(Dop5)-c[Cys-3-I-Tyr-D-Trp-Lys-Val-Cys]- Thr-NH2 DopS-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D-Trp- Lys-Val-Cys]-Thr-NH2 Dop5-D-Lys(Dop5)-Lys-D-Tyr-D-Tyr-c[Cys-3-I-Tyr-D- Trp-Lys-Val-Cys]-Thr-NH2 Dop6-Lys(Dop6)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop7-Lys(Dop7)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop8-Lys(Dop8)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop9-Lys(Dop9)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop10-Lys(Dop10)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop11-Lys(Dop11)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop12-Lys(Dop12)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop13-Lys(Dop13)-c[Cys-3-I-Tyr-D-Trp-Lys-Thr-Cys]- Thr-NH2 Dop6-Lys(Dop6)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop7-Lys(Dop7)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop8-Lys(Dop8)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop9-Lys(Dop9)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys-Thr- Cys]-Thr-NH2 Dop10-Lys(Dop10)-D-Phe-c[Cys-3-1-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop11-Lys(Dop11)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 Dop12-Lys(Dop12)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2 and Dop13-Lys(Dop13)-D-Phe-c[Cys-3-I-Tyr-D-Trp-Lys- Thr-Cys]-Thr-NH2. - From the above description, one skilled in the art can easily ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various uses and conditions. Thus, other embodiments are also within the claims.
Claims (14)
1. A method for synthesizing a therapeutic peptide, the method comprising the steps of:
(a) swelling Fmoc-Sieber resin comprising an Fmoc group in a dipolar aprotic solvent;
(b) de-protecting the Fmoc group of the resin with a solution of piperidine in a dipolar aprotic solvent;
(c) washing the resin after Fmoc de-protection with a dipolar aprotic solvent;
(d) activating an Fmoc-amino acid for coupling to the de-protected resin by dissolving the Fmoc-amino acid and 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) and/or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)/1-hydroxybenzotriazole (HOBt) in a dipolar aprotic solvent, adding a base and stirring;
(e) contacting the activated Fmoc amino acid solution with the resin in a reactor to allow for coupling of the activated Fmoc-amino acid with the resin to form a coupled product;
(f) washing the coupled product;
(g) de-protecting the Fmoc group of the coupled product formed in step (e) or step (j) with a solution of piperidine in a dipolar aprotic solvent;
(h) washing the coupled product after Fmoc de-protection with a dipolar aprotic solvent;
(i) activating an Fmoc-amino acid for coupling to the de-protected coupled product by dissolving the Fmoc-amino acid and 2-(6-chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) (HCTU) and/or 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU)/1-hydroxybenzotriazole (HOBt) in a dipolar aprotic solvent, adding a base and stirring;
(j) contacting the activated Fmoc-amino acid solution with the coupled product in a reactor to allow for coupling of the activated Fmoc-amino acid with the coupled product to form a new coupled product;
(k) washing the coupled product formed in step (j);
(l) repeating steps (g)-(k) until the peptide is formed;
(m) contacting the resin with a cleavage cocktail to cleave the peptide and simultaneously remove side chain protecting groups, resulting in a cleavage mixture and resin;
(n) filtering the cleavage mixture from the resin; and
(o) evaporating the cleavage mixture filtrate and precipitating the crude product from the concentrated solution with an organic solvent to yield a partially purified peptide;
wherein the peptide is a ghrelin analogue of formula I,
R1-A1-A2-A3-A4-A5-R2 (I),
R1-A1-A2-A3-A4-A5-R2 (I),
wherein:
A1 is Apc or Inp;
A2 is D-Bal, D-Bip, D-1Nal, or D-2Nal;
A3 is D-Bal, D-1Nal, D-2Nal, or D-Trp;
A4 is 3Pal, 4Pal, Pff, Phe, Pim, Taz, 2Thi, or Thr(Bzl);
A5 is Apc, Lys, or a bond;
R1 is hydrogen; and
R2 is OH or NH2;
provided that, when A5 is a bond, then:
A4 is Pff, Taz, or Thr(Bzl); or
A1 is Apc and:
A2 is D-Bip or D-Bal;
A3 is D-Bal; or
A4 is 2Thi, 3Pal, or 4Pal.
2. The method of claim 1 , wherein the dipolar aprotic solvents used are each independently selected from the group consisting of: dimethylformamide (DMF); dimethylacetamine (DMA); N-methylpyrrolidone (NMP); and mixtures thereof.
3. The method of claim 1 , wherein the bases used are each independently selected from the group consisting of: N,N-diisopropylethylamine (DIEA); triethylamine (TEA); N-methylmorpholine (NMM); 2,4,6-trimethylpyrimidine (TMP); 2,3,5,6-tetramethylpyridine (TEMP); 2,6-di-tert-butyl-4-dimethylaminopyridine (DBDMAP); 4-dimethylaminopyridine (DHAP); and mixtures thereof.
4. The method of claim 1 , wherein the cleavage cocktail comprises a solution of up to 25% v/v trifluoroacetic acid (TFA), one or more scavengers, and dichloromethane (DCM), and wherein the scavengers are triisopropylsilane (TIPS), triethylsilane (TES), phenol, anisole, thioanisole, water, ethanedithiol (EDT), 1-dodecanethiol, dithiothreitol (DTT) and/or indole.
5. The method of claim 4 , wherein the scavengers are TIPS, TES, anisole and/or water.
6. The method of claim 1 , wherein the peptide comprises tert-butyloxycarbonyl (Boc) and/or tert-butyl ether (tBu) side chain protecting groups and the cleavage cocktail comprises:
15 to 25% v/v TFA, and
2.5 to 12% v/v TIPS,
with the balance being DCM.
7. (canceled)
8. The method of claim 1 , wherein the solution in step (b) comprises piperidine and DMF and the concentration of piperidine is less than 20% (v/v).
9-15. (canceled)
16. The method of claim 1 , wherein A1 is Inp.
17. The method of claim 16 , wherein the peptide is:
18. The method according to claim 1 , wherein A1 is Apc.
19. The method according to claim 18 , wherein the peptide is:
20. The method of claim 1 , wherein, in step (f), the dipolar aprotic solvent is dimethylformamide (DMF).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/332,208 US20170137489A1 (en) | 2011-12-23 | 2016-10-24 | Process for the Synthesis of Therapeutic Peptides |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580089P | 2011-12-23 | 2011-12-23 | |
PCT/IB2012/003056 WO2013093639A1 (en) | 2011-12-23 | 2012-12-21 | Process for the synthesis of therapeutic peptides |
US201414368154A | 2014-06-23 | 2014-06-23 | |
US15/332,208 US20170137489A1 (en) | 2011-12-23 | 2016-10-24 | Process for the Synthesis of Therapeutic Peptides |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/368,154 Continuation US9475837B2 (en) | 2011-12-23 | 2012-12-21 | Process for the synthesis of therapeutic peptides |
PCT/IB2012/003056 Continuation WO2013093639A1 (en) | 2011-12-23 | 2012-12-21 | Process for the synthesis of therapeutic peptides |
Publications (1)
Publication Number | Publication Date |
---|---|
US20170137489A1 true US20170137489A1 (en) | 2017-05-18 |
Family
ID=48095921
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/368,154 Active US9475837B2 (en) | 2011-12-23 | 2012-12-21 | Process for the synthesis of therapeutic peptides |
US15/332,208 Abandoned US20170137489A1 (en) | 2011-12-23 | 2016-10-24 | Process for the Synthesis of Therapeutic Peptides |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/368,154 Active US9475837B2 (en) | 2011-12-23 | 2012-12-21 | Process for the synthesis of therapeutic peptides |
Country Status (14)
Country | Link |
---|---|
US (2) | US9475837B2 (en) |
EP (1) | EP2794634B1 (en) |
JP (1) | JP6192657B2 (en) |
KR (1) | KR101996700B1 (en) |
CN (1) | CN104080795A (en) |
AU (1) | AU2012356321B2 (en) |
BR (1) | BR112014015275A2 (en) |
CA (1) | CA2856257A1 (en) |
ES (1) | ES2663869T3 (en) |
HK (1) | HK1202125A1 (en) |
MX (1) | MX350536B (en) |
RU (1) | RU2625793C2 (en) |
UA (1) | UA115542C2 (en) |
WO (1) | WO2013093639A1 (en) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1937262T3 (en) | 2005-09-29 | 2019-10-31 | Ipsen Pharma | Composition for use in treating gastrointestinal dysmotility |
HUE034308T2 (en) | 2013-03-21 | 2018-02-28 | Sanofi Aventis Deutschland | Synthesis of hydantoin containing peptide products |
CA2907521C (en) | 2013-03-21 | 2021-04-13 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
WO2015134567A1 (en) * | 2014-03-04 | 2015-09-11 | Rhythm Pharmaceuticals, Inc. | Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof |
CN110294789A (en) * | 2018-03-21 | 2019-10-01 | 海南大学 | The synthetic method of the oligopeptides containing DOPA and its application in terms of anti-Parkinson's disease prodrug |
CN110317188B (en) * | 2018-03-29 | 2023-01-17 | 深圳翰宇药业股份有限公司 | Compound and preparation method and application thereof |
WO2020017919A1 (en) * | 2018-07-19 | 2020-01-23 | 한미정밀화학주식회사 | Novel intermediate used for physiologically active polypeptide and method for preparing same |
CN113330021A (en) | 2019-01-24 | 2021-08-31 | 帝斯曼知识产权资产管理有限公司 | Peptide precipitation method |
WO2020167010A1 (en) * | 2019-02-15 | 2020-08-20 | 한미정밀화학주식회사 | Novel intermediate used for biologically active polypeptide and method for preparing same |
WO2021067897A1 (en) * | 2019-10-04 | 2021-04-08 | Tiburio Therapeutics Inc. | Storage stable somatostatin-dopamine chimeric compounds and salt forms thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5117009A (en) * | 1990-08-31 | 1992-05-26 | University Of Minnesota | Xanthenylamide handle for use in peptide synthesis |
US7244721B2 (en) * | 2000-07-21 | 2007-07-17 | Schering Corporation | Peptides as NS3-serine protease inhibitors of hepatitis C virus |
JP3996897B2 (en) | 2001-06-08 | 2007-10-24 | ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス | Somatostatin-Dopamine Chimeric Analog |
JP4276462B2 (en) * | 2002-04-11 | 2009-06-10 | アスビオファーマ株式会社 | Method for producing modified peptide |
TWI331922B (en) * | 2002-08-09 | 2010-10-21 | Ipsen Pharma Sas | Growth hormone releasing peptides |
KR20070102756A (en) * | 2003-04-11 | 2007-10-19 | 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. | Somatostatin-dopamine chimeric analogs |
US8138218B2 (en) * | 2005-07-22 | 2012-03-20 | Ipsen Pharma S.A.S. | Growth hormone secretagogues |
US20100227806A1 (en) * | 2006-03-10 | 2010-09-09 | Tulipano Giovanni | Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment |
WO2007139589A1 (en) * | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
CN101538316B (en) | 2009-01-13 | 2012-09-05 | 深圳翰宇药业股份有限公司 | Method for preparing Eptifibatide with solid phase method |
US20100311946A1 (en) * | 2009-06-03 | 2010-12-09 | Mallinckrodt Inc. | Solid Phase Peptide for the Production of Goserelin |
-
2012
- 2012-12-21 CA CA2856257A patent/CA2856257A1/en not_active Abandoned
- 2012-12-21 WO PCT/IB2012/003056 patent/WO2013093639A1/en active Application Filing
- 2012-12-21 ES ES12840868.9T patent/ES2663869T3/en active Active
- 2012-12-21 MX MX2014007263A patent/MX350536B/en active IP Right Grant
- 2012-12-21 BR BR112014015275A patent/BR112014015275A2/en active Search and Examination
- 2012-12-21 CN CN201280062490.7A patent/CN104080795A/en active Pending
- 2012-12-21 JP JP2014548246A patent/JP6192657B2/en not_active Expired - Fee Related
- 2012-12-21 RU RU2014130277A patent/RU2625793C2/en active
- 2012-12-21 EP EP12840868.9A patent/EP2794634B1/en not_active Not-in-force
- 2012-12-21 US US14/368,154 patent/US9475837B2/en active Active
- 2012-12-21 AU AU2012356321A patent/AU2012356321B2/en not_active Ceased
- 2012-12-21 UA UAA201408394A patent/UA115542C2/en unknown
- 2012-12-21 KR KR1020147020136A patent/KR101996700B1/en active IP Right Grant
-
2015
- 2015-03-16 HK HK15102654.6A patent/HK1202125A1/en unknown
-
2016
- 2016-10-24 US US15/332,208 patent/US20170137489A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2014007263A (en) | 2014-08-01 |
JP2015504045A (en) | 2015-02-05 |
RU2625793C2 (en) | 2017-07-19 |
HK1202125A1 (en) | 2015-09-18 |
EP2794634A1 (en) | 2014-10-29 |
BR112014015275A8 (en) | 2017-06-13 |
WO2013093639A1 (en) | 2013-06-27 |
BR112014015275A2 (en) | 2017-06-13 |
UA115542C2 (en) | 2017-11-27 |
KR20140113696A (en) | 2014-09-24 |
AU2012356321A1 (en) | 2014-07-17 |
MX350536B (en) | 2017-09-08 |
EP2794634B1 (en) | 2018-01-24 |
KR101996700B1 (en) | 2019-07-04 |
JP6192657B2 (en) | 2017-09-06 |
RU2014130277A (en) | 2016-02-20 |
AU2012356321B2 (en) | 2015-09-17 |
US9475837B2 (en) | 2016-10-25 |
CA2856257A1 (en) | 2013-06-27 |
US20150045534A1 (en) | 2015-02-12 |
ES2663869T3 (en) | 2018-04-17 |
CN104080795A (en) | 2014-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20170137489A1 (en) | Process for the Synthesis of Therapeutic Peptides | |
KR101087859B1 (en) | Insulinotropic peptide synthesis | |
US20080287650A1 (en) | High purity peptides | |
JP5199126B2 (en) | Synthesis of glucagon-like peptides | |
US20140128572A1 (en) | Process For Extraction Of Peptides And Its Application In Liquid Phase Peptide Synthesis | |
US20200317721A1 (en) | A process for preparing a glucagon-like peptide | |
CN112912390B (en) | GLP-1 analogues and methods of preparation | |
CN104428310A (en) | Cell penetrating peptides & methods of identifying cell penetrating peptides | |
CN114401981A (en) | Process for producing glucagon | |
US11566058B2 (en) | Process for the preparation of high purity glucagon | |
EP3414257B1 (en) | Method for preparation of liraglutide using bal linker | |
WO2020202182A1 (en) | Process for the preparation of abaloparatide | |
ES2441197T3 (en) | Method for chemical synthesis of polypeptides and proteins | |
CN114945580B (en) | Method for synthesizing south Ji Botai | |
JP3294695B2 (en) | Shaking stabilizer of elcatonin aqueous solution. | |
KR20230110319A (en) | EGF manufacturing method | |
TW201307379A (en) | A process for extraction of peptides and its application in liquid phase peptide synthesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: IPSEN MANUFACTURING IRELAND LIMITED, IRELAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HURLEY, FIONN;WEGNER, KATARZYNA;FOLEY, PATRICK;SIGNING DATES FROM 20140620 TO 20140723;REEL/FRAME:040184/0958 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |